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MULTIFUNCTIONAL AND BIOLOGICALLY 
ACTIVE MATRICES FROM 
MULTICOMPONENT POLYMERIC 
SOLUTIONS 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application claims the benefit of U.S. Provisional 
Application No. 60/666,787, filed Mar. 31, 2005, and U.S. 
patent application Ser. No. 11/395,699, filed Mar. 31, 2006 
now U.S. Pat. No. 7,732,427, of which it is a continuation-
in-part. The contents of each of these priority applications are 
incorporated herein by reference. 
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The work described in this application was sponsored by 
the following Federal Agencies: NSF NIRT under Contract 
Number DMR-0210223, NASA under Contract Number 
NAGS-01923, NIH, Nanoscale Engineering, under Contract 
Number ROI E13003172, and NIH under Contract Number 
RO1-EB006006. 
FIELD OF THE INVENTION 
The present invention relates generally to a composition 
and method for the formation of functionalized polymer 
matrices comprising a matrix polymer, a compatibilizing 
polymer and a biomolecule or other small functioning mol-
ecule. In a more specific embodiment, the invention includes 
heparin-containing electrospun polymeric fibers useful in 
biological applications, for example, implantable systems for 
drug delivery, tissue engineering or wound repair. In other 
aspects the present invention relates to multicomponent poly-
mer matrices that display biologically beneficial properties, 
for example, by also comprising therapeutic molecules 
therein. In another important aspect the invention relates to a 
polymer matrix, useful for the controlled release of a biologi-
cally active agent, such as for example, a drug, a biopolymer, 
a biological macromolecule, and the like. The invention is 
further directed to the formation of functionalized cross-
linked matrices, such as hydrogels, that include at least one 
functionalized compatibilizing polymer capable of assembly. 
BACKGROUND OF THE INVENTION 
Over the past two decades the development of novel drug 
delivery systems has had a tremendous impact on medicine, 
allowing for the improvement of many existing therapeutics 
as well as enabling the use of entirely new therapies. Along 
with these improvements there has been a move to miniatur-
ize drug delivery devices from the macroscale (>I mm) to the 
macroscale (100-0.01 µm) or nanoscale (100-1 mu). One goal 
of developing these devices is to provide for the in situ deliv-
ery of therapeutic compounds. Therefore, a main area of 
investigation concerns the development of integrated systems 
that combine the nanotechnology with therapeutic molecules, 
for example, drugs, or biopolymers. 
However, these new technologies must overcome several 
crucial and significant obstacles. For example, new 
approaches are required that allow for the delivery of 
insoluble, or unstable compounds. In addition, these 
approaches must address situations in which the therapeutic 
molecule is rare, or difficult to purify. Furthermore, these 
approaches must allow for localized delivery of potent com- 
2 
pounds, and provide for improved compliance by reducing 
the chances of missing or erring in a dose. Lastly, these 
devices cannot be so small that they are unable to deliver an 
adequate dose. 
5 	 In addition, to date a number of peptides and proteins have 
been explored for pharmaceutical applications by virtue of 
their high biological activity and specificity. Despite potential 
advantages offered by these drugs, their application may suf-
fer because of the high molecular weight, hydrophilicity and 
10 low stability, which are reflected in poor biopharmaceutical 
properties. In particular, peptides and proteins undergo rapid 
clearance from the body, which takes place by a combination 
of events including proteolysis, renal ultrafiltration, and liver 
15 clearance. 
The development of functionalized polymers that can elicit 
specific biological responses, as well as the development of 
methods to fabricate these biologically functionalized poly-
mers, is a viable approach for such therapeutic applications, 
20 in which delivery of molecules such as those above is desir-
able. For example, the generation of fibrous matrices with 
biological properties and fiber diameters commensurate with 
those of the natural extracellular matrix (ECM) may permit 
the development of novel materials for use not only in drug 
25 delivery, but also in wound healing or tissue engineering. 
Synthetic polymers, which can be designed to mimic some 
functions of biopolymers, have been actively developed as 
drug delivery matrices due to their industrial and scientific 
value. They represent a primary polymeric vehicle for the 
3o delivery of drugs and biomolecules, owing to their simple 
synthesis, ease of processing, and range of physical proper-
ties. Polymers such as proteins, polysaccharides, and nucleic 
acids, which are present as basic components in living organic 
systems, have also found some use in drug delivery and bio- 
35 materials applications, particularly for biopolymers such as 
collagen and alginate, which have desired mechanical and 
biological properties. There remains a significant need, how-
ever, for the facile production of polymeric materials in which 
mechanical and biological properties can be easily modified 
40 in a modular fashion, without relying solely on the naturally 
occurring mechanical properties of the biological polymers 
or the lack of biological activity of synthetic polymers. 
One approach to the use of polymers in drug delivery 
applications involves the response of a polymer system to 
45 certain stimuli, which is a common process for biopolymers 
in living organisms. Stimuli responsive polymers can provide 
a variety of applications for the biomedical fields. The interest 
in these polymers has increased dramatically due to their 
promising potential. Among others, temperature and pH 
5o responsive mechanisms have been investigated as they are 
relatively convenient and effective stimuli in a variety of 
applications. Such stimuli-responsive polymers have been 
utilized in various forms, including cross-linked (perma-
nently) hydrogels, reversible hydrogels, micelles, modified 
55 interfaces, and conjugated solutions, among others. 
There has also been developing interest by the scientific 
community in applying methods from engineering and the 
life sciences to create artificial constructs directed to tissue 
regeneration, and thus, providing a minimally invasive and 
60 less painful way to treat patients. The basic protocol for the 
tissue engineering approach includes isolating specific cells 
by obtaining them through a biopsy from a patient, growing 
them on a three-dimensional scaffold under controlled cul-
ture conditions, delivering the construct to the desired loca- 
65 tion in the patient's body and directing new tissue formation 
into the scaffold that will be degraded over time. Successful 
regeneration of damaged organs or tissues based on tissue 
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engineering requires several critical elements, not the least of 
which includes biomaterial scaffolds that serve as a mechani-
cal support for cell growth. 
Materials are important in most tissue engineering strate-
gies as they can serve as a substrate on which cell populations 
can attach and migrate, be implanted with a combination of 
specific cell types as a cell delivery vehicle, and be utilized as 
a drug carrier to activate specific cellular function in the 
localized region. 
The modification of biomaterials with bioactive molecules 
has been found useful in designing biomimetic scaffolds that 
can provide biological cues to elicit specific cellular 
responses and direct new tissue formation. The surface and 
bulk modification of materials withpeptide sequences or with 
bioactive proteins or other biomolecules, for example, can 
allow for the modulation of cellular functions such as adhe-
sion, proliferation and migration through alterations of pep-
tide concentration or its spatial distribution. A variety of cell 
binding peptides have been introduced into three dimensional 
networks through physical, chemical, photochemical, and 
ionic crosslinking. The molecules have been attached to a 
variety of polymeric substrates for varying applications, but a 
need still remains for methods for simple modification of 
materials with multiple bioactive molecules in a manner that 
can control their release. 
Electrospinning is an attractive approach to polymer pro-
cessing. The control of fiber diameter, porosity, and fiber 
surface morphology makes electrospun fibers useful in a 
range of applications including filtration, electronic, and bio-
medical applications. Electrospun fibers are ideal for use in 
biomedical applications such as tissue engineering and drug 
delivery due to the three-dimensional nanometer scale matrix 
that can be quickly produced using small quantities of starting 
material (<50 mg) on the laboratory scale. Larger matrices 
can also easily be made via the scaling up of materials that 
prove to have useful materials and biological properties on the 
laboratory scale. Collagen, fibrinogen, chitosan, poly(lactic 
acid), poly(L-lactide-co-p-caprolactone), and poly(D,L-lac-
tide-co-glycolide) are just a few of the polymers being inves-
tigated for use in electrospun drug delivery and tissue engi-
neering constructs due to their biocompatibility. Electrospun 
fibers mimic the size scale of fibrous proteins found in the 
extracellular matrix (50-150 mu) and the three-dimensional 
nature of the matrix allows for cells to infiltrate the matrix and 
proliferate. A variety of additional polymers can also be elec-
trospun into matrices for drug delivery, tissue engineering, 
and other applications. For example, see Z. M. Huang, Y. Z. 
Zhang, M. K. Kotaki and S. Ramakrishna, Composites Sci. 
and Tech. 2003, 63, 2223-2253, (US Patent publication No. 
US20030137069). 
Although there have been reports of the use of electrospun 
fibers as scaffolds for select drug delivery and biomaterials 
applications, the incorporation of bioactive molecules has not 
been widely exploited. In one example, tetracycline was 
included in a solution of poly(lactic acid) (PLLA) and poly 
(ethylene-co-vinyl acetate) and electrospun in a fiber mem-
brane to study the release profile of the fiber-encapsulated 
drug. PLLA has also been studied as a matrix to incorporate 
the drugs rifampin (to treat tuberculosis) and paclitaxel (anti-
cancer drug). Polymers loaded with both of these therapeutic 
molecules could be fabricated into nanometer to micron 
diameter electrospun PLLA fibers and used for delivery of the 
drug. 
While the development of functionalized polymers that can 
elicit specific biological responses is of great interest in the 
biomedical community, as well as the development of meth-
ods to fabricate these biologically functionalized polymers, 
4 
there is still a need for more facile methods to create biologi-
cally active functionalized matrices that permit immobiliza-
tion and long-term delivery of biomolecules and other small 
functioning molecules, moieties, and/or particles. 
5 	 For example, although there have been studies demonstrat- 
ing the utility of functionalizing electrospun fibers, the func-
tionalization of electrospun fibers to confer specific biologi-
cal activity would be particularly advantageous for many 
biomaterial applications, as such modification would permit 
to the fabrication of biomaterials that are structurally relevant 
and that possess properties designed to treat or address spe-
cific problems. In addition, such incorporation could serve to 
protect bioactive molecules, release them in relevant time- 
15 frame, and incorporate multiple such molecules. In particular, 
the development of simple methods to produce multifunc-
tional electrospun fibers would advance the development of 
electrospun fibers for biomedical applications. 
Of such bioactive molecules, glycosaminoglycans have 
20 been demonstrated to mediate a wide range of biological 
activities such as cell adhesion, cell mobility, cell prolifera-
tion and tissue morphogenesis via binding to various cell 
regulatory proteins such as the chemokines, growth factors, 
enzymes, enzyme inhibitors, and extracellular matrix pro- 
25 teins. The well studied glycosaminoglycan, heparin, is a lin-
ear, unbranched, highly sulfated polysaccharide chain, and it 
is well accepted that the electrostatic interactions between the 
sulfates of the glycosaminoglycan and basic residues of a 
protein play an important role in binding. In particular, the 
30 spatial orientation of the basic residues is a major determinant 
of heparin-binding ability, and variations in the pattern of the 
sulfation of the heterogeneous heparin therefore permit bind-
ing between heparin and a wide range of binding partners. 
Accordingly, heparin has been incorporated into covalent 
35 hydrogel delivery systems because of this ability to bind a 
diverse set of proteins. In addition, we and others have dem-
onstrated that the interactions between heparin and specific 
HBPs can also mediate the assembly of noncovalently asso-
ciated hydrogel networks (see, for example, N. Yamaguchi, 
4o K. L. Kiick, Polysaccharide poly (ethylene glycol) star 
copolymers as scalolds for the production of bioactive hydro-
gels, Biomacromolecules 6 (4) (2005) 1921-1930; N. 
Yamaguchi et al., Rheological characterization of polysac-
charide poly(ethylene glycol) star copolymer hydrogels, 
45 Biomacromolecules 6 (4) (2005) 1931-1940; B. L. Seal, A. 
Panitch, Physical polymer matrices based on affinity interac-
tions between peptides and polysaccharides, Biomacromol-
ecules 4 (6) (2003) 1572-1582). 
Because hydrogels can mimic the high water content and 
50 mechanical properties of natural tissues, they are prime can- 
didates as carriers of bioactive agents, in bioadhesive sys- 
tems, or as biorecognizable materials. Given that poly (eth- 
ylene glycol), or PEG, is highly hydrophilic and generally 
nonadhesive to proteins or cells, it has found widespread use 
55 as a drug carrier, and many PEG hydrogels have been pro- 
duced from aqueous solutions containing linear or branched 
PEG macromolecules via chemical crosslinking. In addition 
to hydrogels formed via radical crosslinking reactions, PEG 
hydrogels have been formed, for example, via Michael-type 
6o addition reactions upon mixing with thiol-bearing com- 
pounds or via the reaction between amino-terminated poly 
(ethylene glycol) and the herbal iridoid glycoside genipin. In 
some cases, cell adhesive peptide domains or biodegradable 
sequences have been introduced into PEG hydrogels to 
65 endow them with more biological signaling functions,includ- 
ing the capacity for growth factor delivery. Accordingly, there 
have been a variety of covalently crosslinked hydrogel sys- 
US 8,338,390 B2 
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tems developed to deliver growth factors via mechanisms 
such as diffusion and chemical or enzymatic reaction. 
Noncovalent interactions provide an alternative method for 
crosslinking, as introduced above, removing the need for 
toxic chemical crosslinking agents in gel preparation. In addi-
tion, noncovalent crosslinking strategies may offer advan-
tages in maintaining protein integrity and bioactivity until 
delivery. Polymer hydrogels have been formed via specific 
recognition events such as reversible antibody-antigen inter-
actions (see T. Miyata et al., A reversibly antigen-responsive 
hydrogel, Nature 399 (6738) (1999) 766-769) and coiled-coil 
interactions (see for example, C. Y. Xu et al., Reversible 
hydrogels from self-assembling genetically engineered pro-
tein block copolymers, Biomacromolecules 6 (3) (2005) 
1739-1749; C. Wang et al., Hybrid hydrogels assembled from 
synthetic polymers and coiled-coil protein domains, Nature 
397 (6718) (1999) 417-420; W. A. Petka, et al., Reversible 
hydrogels from self-assembling artificial proteins, Science 
281 (5375) (1998) 389-392). There has been little attention 
given, however, to the interaction between peptides (particu-
larly coiled-coils) and polysaccharides in hydrogel assembly. 
Further, the fabrication of biologically active fibers through 
such functionalization strategies is a fairly new and unex-
plored area in the field of electrospinning, and electrospun 
fibers have not been investigated for their ability to incorpo-
rate growth factor binding glycosaminoglycans, such as hep-
arin, in a manner designed to control release. 
SUMMARY OF THE INVENTION 
The invention is directed to a functionalized polymer 
matrix for the in vitro or in vivo delivery of a therapeutic 
compound, the polymer matrix comprising a growth factor, 
wherein growth factor release exhibits a controlled-release 
profile from the polymer matrix over at least seven days. 
The invention is further directed to a functionalized poly-
mer matrix comprising a matrix polymer, a compatibilizing 
polymer comprising PEG, and a small molecule comprising a 
low molecular weight heparin peptide that is covalently 
attached to the compatibilizing polymer, wherein the polymer 
matrix comprises between about 0.35% wt/wt and about 
0.95% wt/wt compatibilizing polymer. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a scanning electron micrograph of PEO/LMWH-
dye electrospun fibers. 
FIG. 2 shows Laser Scanning Confocal Microscopy 
(LSCM) images of electrospun PEO fibers (a) transmitted 
light and (b) fluorescence (5 µm scale bar). 
FIG. 3 is an LSCM image of electrospun PEO/LMWH-dye 
fibers (5 µm scale bar). 
FIG. 4 is a scanning electron micrograph of electrospun 
PEO/PEG-LMWH-dye fibers. 
FIG. 5 is an LSCM image of PEG-LMWH-dye/PEO elec-
trospun fibers (5 M scale bar). Dark and colored regions are 
caused by folds in the surface of the macroscopic sample; not 
by composition variations. 
FIG. 6 shows scanning electron micrographs of (a) PLGA 
electrospun fibers, (b) PLGA/LMWH-dye fibers, and (c) 
PLGA/PEG-LMWH-dye fibers. 
FIG. 7 shows LSCM images of electrospun PLGA fibers 
(a) transmitted light and (b) fluorescence (10 µm scale bars). 
FIG. 8 shows LSCM images of electrospun (a) LMWH-
dye/PLGA fibers and (b) PEG-LMWH-dye/PGLA fibers and 
(c) z-stack of PEG-LMWH/PLGA fibers (10 µm scale bars). 
6 
FIG. 9 shows bFGF binding on electrospun fibers. Eachbar 
indicates ±standard deviation of the average of three measure-
ments. 
FIG. 10 shows scanning electron microscopy images of 
5 PEG-LMWH-dye/PLGA fibers and LMWH-dye/PLGA 
fibers after incubation in PBS for 6 h, 1 day, 3 days, and 14 
days. 
FIG. 11 shows retention of heparin within electrospun 
matrices as observed by multiphoton microscopy for the 
10 PEG-LMWH-dye/PLGA fibers and LMWH-dye/PLGA 
fibers after incubation in PBS for 6 h, 1 day, 3 days, and 14 
days (10 µm scale bars). 
FIG. 12 shows retention of PEG-LMWH-dye within depth 
of the electrospun matrix after 14 days of incubation in PBS 
15 as imaged via multiphoton microscopy. 
FIG. 13 depicts the release of bFGF from PLGA, LMWH-
Dye, and PEG-LMWH-Dye electrospun fibers after 5 h and 
24 h incubation in PBS. 
FIG. 14 is a digital picture displaying the visual differences 
20 observed in the binding of bFGF to PLGA, LMWH-Dye, and 
PEG-LMWH-Dye electrospun fibers after 5 h and 24 h incu-
bation in PBS. 
FIG. 15 shows the results from the BrdU cell proliferation 
assay. Each bar indicates ±standard deviation of the average 
25 of three measurements. 
FIG. 16 provides LSCM images of (a) LMWH/PLGA and 
(b) PEG-LMWH/PLGA fibers (blue) incubated for 8 days 
with MG63 cells (green) (10 µm scale bars). 
FIG. 17 shows (a) CD spectra of PEG-PF4ZIP at different 
30 concentrations in PBS at 25° C.; (b) Concentration depen-
dence of the MRE for PEG-PF4ZIP at 222 mu. The solid line 
is the best fit. 
FIG. 18 is a schematic of the assembly of hydrogels from 
solutions of the two polymer conjugates. The PF4ZIP is ren- 
35 dered as an oligomerized coiled-coil, as its concentration 
(200 µM) under these experimental conditions is two orders 
of magnitude greater than the measured Kd value. 
FIG. 19 depicts storage moduli (closed symbols) and loss 
moduli (open symbols) of the PEG-LMWH/PEG-PF4ZIP 
40 hydrogels for different molar ratios. The response of 2.5 wt ° 
A) of the PEG-LMWH (circles) is shown for comparison. 
FIG. 20 shows plots of normalized storage moduli G' 
(w-0.1 Hz) as a function of HBP (PF4ZIP, ATIII or HIP) to 
LMWH. HIP and ATIII data are adapted from reference 12. 
45 FIG. 21 is a comparison of storage moduli (closed sym-
bols) and loss moduli (open symbols) of the PEG-LMWH/ 
PEG-PF4ZIP hydrogels (LMWH:PF4ZIP=9:0.5) obtained 
25° C. and 37° C. 
FIG. 22 shows shear recovery data for PEG-LMWH/PEG-
50 PF4ZIP hydrogels (LMWH:PF4ZIP=9:0.5) at 25° C. and 37° 
C. 
FIG. 23 depicts the bFGF release and hydrogel erosion 
profiles of the PEG-LWMH/PEG-PF4ZIP hydrogel 
(LMWH:PF4ZIP=8:1) and the PEG-LMWH/PEG-HIP 
55 hydrogel (LMWH:HIP 8:2). The errors are derived from the 
average of at least duplicate measurements. 
FIG. 24 shows graphs of the release of growth factors from 
electospun materials. (a) PDGF release from PLGA-based 
materials; (b) VEGF release from PU-based materials, (c) 
60 FGF release from collagen-based materials. 
DETAILED DESCRIPTION OF THE INVENTION 
The present invention relates generally to a composition 
65 and method for the formation of functionalized polymer 
matrices comprising a matrix polymer, a compatibilizing 
polymer and a biomolecule or other small functionalizing 
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molecule. The invention is a novel strategy for the incorpo- 	 preferably LMWH, into an electrospun matrix via its attach- 
ration of low molecular weight, biologically active molecules 	 ment to a star PEG polymer provides increased growth factor 
(or molecules with other activities, e.g. sugars, peptides, 	 binding to the electrospun matrix. The increased growth fac- 
polysaccharides, polypeptides, dyes, electroactive groups, 	 tor binding is due to the conjugation of LMWH to the PEG 
etc.) into a fibrous or other matrix. The biological (or other) 5 molecule. The PEG-LMWH molecule takes longer to diffuse 
molecules are conjugated to an intermediate molecular 	 out of the matrix, therefore allowing for more growth factor 
weight polymer or "compatibilizing polymer" (e.g., but not 	 binding to occur within a given time period as shown by 
limited to: linear, star, hyperbranched) to allow retention of 	 comparing the amount of growth factor binding to the PEG- 
the biomolecule in its bioactive form in fibers and other forms 	 LMWH matrix versus a matrix consisting of LMWH alone 
of polymeric materials (e.g. films, gels, solids, particles, etc.). io (See Example 1). 
Facile functionalization of electrospun fibers and other mate- 	 In the case of electrospun matrices, while there are limita- 
rials with other low molecular weight, bioactive polysaccha- 	 tions to what polymers can be electrospun, there are many 
rides and peptides (and other molecules) is contemplated by 	 possible uses. Solubility of fibers must be controlled, but such 
this invention. Such functionalization is important because 	 control is also possible with this invention as well as matching 
biological processes are controlled via multiple and different 15 of mechanical properties for specific applications that are 
signaling molecules that have distinct spatial and temporal 	 accomplished using appropriate choice of polymer, additives, 
release profiles, and the rate of their release from the fibers 	 and/or processing protocols. 
can be controlled with the technology of this invention. 	 Matrix Polymer 
The invention is currently demonstrated in a preferred 
	
Matrix polymers, effective in this invention include but are 
embodiment comprising a low-molecular-weight-heparin 20 not limited to: Nylon 6,6; Nylon 6,10; (other nylons, also), 
(LMWH)-modified star copolymer incorporated into electro- 	 polyurethanes, polyacrylonitrile, polyvinyl alcohol, polylac- 
spun fibers. Attachment of active molecules to intermediate 	 tic acid, polyethylene-co-vinyl acetate, polycarbonate, poly 
molecular weight polymers provides effective retention of the 	 (iminocarbonate)s, polymethacrylates, poly(alkyl meth- 
molecules in the material over time scales relevant for bio- 	 acrylic acid)s, polyacrylates, poly(alkyl acrylic acid)s, poly 
logical and other potential applications. The choice of inter-  25 (N,N'-diethylaminoethyl 	 methacrylate), 	 poly(N,N'- 
mediate molecular weight compatibilizing polymer will per- 	 dialkylaminoalkyl acrylamides), poly(heylene oxide)/PEO, 
mit control over retention and release rate of the molecule or 	 polyethylene terephthalate, polystyrene, polyvinyl chloride, 
other active species. 	 poly vinyl phenol, polyacrylamide, poly(N-alkyl acrylamide) 
Advantages of using a polymer-conjugated biomolecule 	 s, poly lactic-co-glycolic acids, polycaprolactone, poly(2- 
(i.e. polymer conjugate) for incorporation of bioactive moi-  3o hydroxyethyl methacrylate) (polyHEMA), poly(vinylidene 
eties into materials as provided by the invention, in place of 
	
fluoride), poly(vinylidene chloride), poly(ethylene glycol)/ 
covalent attachment of the biomolecule to a high molecular 	 PEG, polyvinyl pyrrolidone, polyethylene, polypropylene, 
weight polymer used directly in material formation, are sev- 	 poly(3-hydroxybutyrate), poly(ortho esters), polyanhy- 
eral-fold. For instance, they include i) the use of a polymer 	 drides, poly(ether-ester) azopolymers, poly(dimethyl silox- 
conjugate of the invention does not require a need for the 35 ane), poly(phosphazene)s, other copolymers of the above 
development of distinct chemistry relevant for a particular 	 homopolymers (e.g. poly(methacrylic acid-co-ethylene gly- 
molecule/polymer pair used in the material, as any polymer 	 col), and others. 
conjugate could be incorporated into any polymeric matrix; 	 Matrix polymers may also comprise natural polymers, 
ii) the use of a polymer conjugate of the invention does not 	 such as collagen, silk, silk-like protein polymers, elastin, 
limit the number of molecules that could be incorporated into 40 elastin-like protein polymers, poly(amino acids), cellulose 
a given material for a given set of chemical transformations; 	 acetate, hyaluronic acid, chitosan, fibronectin, and others. 
iii) in biological applications, the incorporation of biomol- 	 Combination fibers comprising mixtures of different syn- 
ecules via the current invention permits their controlled 	 thetic and/or natural polymers can also be prepared. Polymer 
release in soluble form; iv) it is easier to control release rate 	 combinations help to optimize solubility and mechanical 
and inclusion of multiple molecules at varying ratios/ 45 properties of the fibers. 
amounts than when a bio (or other) molecule must be 	 Composite materials comprising any of the above poly- 
covalently attached directly to the polymers of the material; 	 mers and an appropriate inorganic matrix (clays, silicates, 
and v) the incorporation of biomolecules into materials via 	 microparticles, etc.) can also be employed as a matrix poly- 
this invention allows not only control over release rates, but 	 mer for applications requiring high mechanical strength, such 
permits facile incorporation of multiple biological (or other 5o as hard tissue engineering applications. 
active) species into materials, and offers the potential for each 	 For drug delivery and biological applications, the follow- 
species to have a separate and distinct release rate. 	 ing are particularly preferred: Poly(ethylene), poly(propy- 
The materials may find application in drug delivery or 	 lene), poly(vinyl chloride), poly(vinyl alcohol), poly(ethyl- 
tissue engineering scaffolds to promote tissue repair and/or 	 ene-vinyl acetate), poly(enol-ketone), poly(acrylic acids), 
regeneration. They could be useful in other materials in 55 poly(acrylamides), poly(N-alkyl acrylamides), poly(alkyl 
related applications where controlled release of a multiple of 	 acrylates), PEG, PEO, poly(tetrafluoroethylene), poly(gly- 
active ingredients is desired, e.g. biosensors, detoxification, 	 colic acid), poly(lactic acid), poly(lactic -co -glycolic acid), 
DNA delivery, etc. 	 poly(caprolactone), poly(3-hydroxybutyrate), poly(ortho 
An important, overriding difference of the invention from 	 esters), poly(anhydrides), poly(amido amines), poly(ure- 
the prior art is that it allows for molecules (e.g. growth factors, 60 thanes), poly(dimethyl siloxane), poly(phosphazenes), 
proteins, peptides, and other non-biological molecules, etc.) 	 among others. In addition, collagen, silk, silk-like protein 
to be incorporated into a polymer matrix via compatibiliza- 	 polymers, elastin, elastin-like protein polymers, poly(amino 
tion of the molecules with the polymer matrix, and that it 	 acids), cellulose acetate, hyaluronic acid, chitosan, fibronec- 
further allows for the controlled incorporation and release of 	 tin, and others, may also be used. 
a variety of different molecules from a polymeric matrix. For 65 	 For applications in which a molecule is to be released in a 
example, in the preferred embodiment (described in more 	 non-biological environment (e.g., water purification, agricul- 
detail in example 1), the incorporation of heparin, and more 	 tural treatments, biosensors, smart fabrics, etc.), any of the 
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above polymers could be employed; specific polymers would 
be chosen on the basis of the specific application. 
Compatibilizing Polymer 
Any moderate molecular weight polymer, of the chemical 
compositions of the above matrix polymers, that can be modi-
fied via reasonable chemical means with a biomolecule or 
other small functional molecule, moiety, or particle is con-
sidered a compatibilizing polymer according to this inven-
tion. Moderate molecular weight preferably comprises, but is 
not limited to, a molecular weight of approximately 1/2 to'/i000 
the molecular weight of the matrix polymer it is bound to, in 
such a range that the compatibilizing polymer permits homo-
geneous incorporation of the biomolecule into the matrix 
polymer and sufficiently slows the diffusion-based release of 
the biomolecule over timescales relevant for a particular 
application. Some examples of moderate molecular weight 
polymers that would function effectively as a compatibilizing 
polymer in this invention include synthetic degradable poly-
mers such as poly(glycolic acid), poly(lactic acid), poly(eth-
ylene glycol) (PEG), poly(lactide-co-glycolide), and poly(e-
caprolactone) and others. 
Additional polymers include polymers that could function 
as the matrix polymer, such as: poly(acrylic acids), poly(acry-
lamides), poly(N-alkyl acrylamides), poly(alkyl acrylates), 
poly(3-hydroxybutyrate), poly(ortho esters), poly(anhy-
drides), poly(amido amines), poly(urethanes), poly(dimethyl 
siloxane), poly(phosphazenes), among others. In addition, 
collagen, silk, silk-like protein polymers, elastin, elastin-like 
protein polymers, poly(amino acids), cellulose acetate, 
hyaluronic acid, chitosan, fibronectin, and others, may also be 
used. As the compatibilizing polymer can be functionalized at 
chemical groups located along the length of the polymer 
chain or at the termini of the polymer, many polymers can be 
employed. Potential additional polymers include: Nylon 6,6; 
Nylon 6,10; (other nylons, also), polyurethanes, polyacry-
lonitrile, polyvinyl alcohol, polyethylene-co-vinyl acetate, 
polycarbonate, poly(iminocarbonate)s, polymethacrylates, 
poly(alkyl methacrylic acid)s, polyacrylates, poly(alkyl 
acrylic acid)s, poly(N,N'-diethylaminoethyl methacrylate), 
poly(N,N'-dialkylaminoalkyl acrylamides), polyethylene 
terephthalate, polystyrene, polyvinyl chloride, poly vinyl 
phenol, polyacrylamide, poly(N-alkyl acrylamide)s, poly(2-
hydroxyethyl methacrylate) (polyHEMA), poly(vinylidene 
fluoride), poly(vinylidene chloride), polyvinyl pyrrolidone, 
poly(3-hydroxybutyrate), polyanhydrides, poly(ether-ester) 
azopolymers, poly(dimethyl siloxane), poly(phosphazene)s, 
other copolymers of the above homopolymers (e.g. poly 
(methacrylic acid-co-ethylene glycol), and others. 
A preferred compatibilizing polymer for use in this inven-
tion is poly (ethylene glycol) or PEG. PEG is a linear or 
branched neutral polyether with the chemical formula HO 
(CH2CH2)„ H. PEG is highly soluble in water and many 
organic solvents (e.g., methylene chloride, ethanol, toluene, 
acetone, and chloroform), and is readily available in various 
sizes and functionalized architectures (e.g., amino-, car-
boxyl-, and sulfhydryl-terminated). Low-molecular weight 
(<100 daltons) PEGS are viscous and colorless liquids, 
whereas high-molecular weight PEGS are waxy solids whose 
melting points are proportional to their molecular weights 
with an upper limit near 67° C. PEG has been found to be 
nontoxic and is approved by the FDA for use in drugs (paren-
tals, topicals, suppositories, nasal sprays), foods, and cosmet-
ics. Molecular weights of PEG used in biomedical applica-
tions usually range between a few hundred to 20,000 Da. The 
molecular weight distribution of these PEG polymers is gen-
erally low, but the commonly used mono-methyl ethers of 
PEG exhibit broader molecular weight distributions. In solu- 
10 
tion, PEG is also a highly hydrated polymer, where each 
monomer (ethylene oxide unit) can bind three molecules of 
water. PEG polymer exhibits a large degree of segmental 
flexibility in aqueous solution and it is thought that PEG has 
5 the ability to influence the structure of several molecular 
layers of more loosely associated hydrating water molecules. 
PEG is valued for its ability to exclude other polymers 
(natural and synthetic) from its presence in aqueous environ-
ment. This exclusion of other polymers is the primary driving 
to force behind PEG's ability to reject proteins, from two-phase 
systems with other synthetic polymers, and makes this poly-
mer both nonimmunogenic and nonantigenic. Because of its 
many benefits, PEG is ideally suited for protein modification. 
15 Indeed, PEG is currently considered one of the most success-
ful techniques to prolong the residence time of protein drugs 
in the bloodstream. There are dozens of examples of PEG-
protein conjugates described in the literature. For example, 
PEG has been considered a tool to enhance drug delivery to 
20 neoplastic tissues such as, for instance, pegylated proteins 
that have been applied in passive tumor-targeting while pegy-
lated monoclonal antibodies or MoAb fragments have been 
investigated as immunotargeting agents. (see, for example 
Sato H., Enzymatic procedure for site-specific pegylation of 
25 proteins, ADVANCED DRUG DELIVERY REVIEWS 54 
(4): 487-504 Jun. 17, 2002; Deiters A., et al., Site-specific 
PEGylation of proteins containing unnatural amino acids, 
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 
14 (23): 5743-5745 Dec. 6, 2004; Hermanson, Greg T., Bio- 
30 conjugate Techniques, 1s t edition, Academic Press, New 
York, 1996) (All of which are herein incorporated by refer-
ence in their entirety). 
PEG conjugation technology has been used, for example, 
to improve the therapeutic efficacy of recombinant human 
35 proteins because it alleviates many problems associated with 
therapeutic protein formulations. For example, the attach-
ment of PEG to a protein affects its molecular size, charge, 
and receptor-binding capabilities, which can serve to 
decrease the conjugate's overall rate of clearance from the 
4o body. Also, by sterically shielding the protein domains sus-
ceptible to proteolytic attack, PEG decreases the protein deg-
radation that causes protein biological inactivity. Finally, by 
sterically masking a therapeutic protein's immunogenic/an-
tigenic determinants, PEG conjugation commonly results in 
45 conjugates that are nonimmunogenic and nonantigenic. The 
result of changes in the parental protein's characteristics by 
PEG almost invariably increases the plasma half-life and 
resistance to proteolytic degradation, and decreases immuno-
genicity and antigenicity of the resultant PEG-protein conju- 
50 gate. Although PEG is generally considered to be non-immu-
nogenic, its parenteral administration has been found to 
stimulate the production of antibodies. 
Small Functioning Molecule 
Small functioning molecules according to this invention 
55 include, but are not limited to, biomolecules and functional 
molecules such as peptides, sulfated peptides/polypeptides, 
peptides/polypeptides with other functionalization/modifica-
tions, peptides/polypeptides containing non-natural amino 
acids, polypeptides (natural AA, sulfated, non-natural AA, 
60 other modified side chains, etc.), protein fragments, proteins 
(e.g., growth factors, growth hormones, cytokines, insulin, 
etc.), enzymes, saccharides, oligosaccharides, polysaccha-
rides, small molecule drugs (e.g., doxorubicin, aspirin, adria-
mycin, tetracycline (antibiotic), chloroquine (antimalarial), 
65 tamoxifen, and other small molecule drugs that can be chemi-
cally conjugated to a polymer), dyes, organics, metals, and 
nanoparticles and nanomolecules. 
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One particularly interesting biomolecule is heparin. Hep- 	 or liposomal solutions, or emulsions), or spray crosslinking 
arin is a highly sulfated glycosaminoglycan that binds growth 	 can be used to form particulate and nanoparticulate polymers. 
factors such as fibroblast growth factor (FGF), vascular 	 Crosslinking of monomer solutions in a mold or microfluidic 
endothelial growth factor (VEGF), heparin-binding epider- 	 channel permits the construction of a matrix of essentially any 
mal growth factor (HBEGF), transforming growth factor-13 5 shape/size. Films cast of the monomer solutions (e.g., via 
(TGF-13), and others. Those having skill in the art are clearly 	 spincoating, doctor blade application, dipcoating, etc.) can 
aware that growth factors are important for controlling cellu- 	 also be produced via crosslinking by any of the above mecha- 
lar activities such as cell growth and proliferation. The incor- 	 nisms or via simple casting/drying of a non-water soluble 
poration of heparin in the electrospun matrix is of functional 	 polymer. 
importance owing to heparin's role as a binding site for many 10 	 Electrostatic fiber spinning, or "electrospinning," is a pre- 
growth factors; sulfated peptides may have similar activity 	 ferred process for this invention. Electrospinning is a process 
and would therefore also be useful for similar reasons. For 	 by which superfine fibers, ranging from approximately 10 
example, the binding of growth factors to glycosaminogly- 	 nanometers to about 10 microns in diameter, are formed. The 
cans in the ECM is essential for storage, release, and preser- 	 resulting electrospun fiber web has a high specific surface 
vation of the bioactivity of the growth factor. Heparin prima-  15 area that is beneficial in a wide variety of technologies due to 
rily serves to immobilize growth factors until release but is 	 the small fiber diameter and its porous structure. A high 
also known to control their mitogenic activity, and in several 	 voltage source is used during the electrospinning process to 
cases, serves as a cofactor to promote binding of the growth 	 generate an electrically charged jet of polymer solution or 
factors to their receptors. Heparin is also known to regulate 	 melt expelled from a device such as a pipette. This process is 
the growth of fibroblast and endothelial cells when combined 20 then followed by a drawing of the resulting filaments as they 
with heparin-binding growth factors. For example, heparin 	 solidify or coagulate. Electrospinning provides a simple 
has been reported to have been incorporated into a chitosan 	 approach for production of solid, as well as hollow, one- 
hydrogel where it was found to induce neovascularization in 	 dimensional nanofibers from a variety of starting materials. 
vivo and enhanced the activity of acidic fibroblast growth 
	
To date, dozens of synthetic or natural polymers, melts, and 
factor (aFGF) and basic fibroblast growth factor (bFGF) and 25 polymer blends have been successfully spun using the elec- 
stabilized the growth factors in vitro. A variety of other 	 trospinning process. (see, for example, Shin et al., Biomate- 
reports also confirm the benefits of including heparin in a bulk 	 rials 2003, 24, 4353-4364; Sukigara et al, Polymer 2003, 44, 
hydrogel matrices, such as those comprising fibrin, PEG, 	 5721-5727 (Frank Ko); Li et al, J. Biomed. Mater. Res. 2002, 
collagen, hyaluronic acid, and synthetic polymers, and the 	 60, 613-621 (Frank Ko); 7in et al., Biomacromolecules 2002, 
extension to a fibrous matrix may provide additional struc-  30 3, 1233-1239 (David Kaplan); Tin et al., Biomaterials, 2004, 
tural advantages for producing materials that mimic the 	 25, 1039-1047 (David Kaplan); Farach-Carson, M. C.; Wag- 
ECM. Incorporation of biomolecules such as heparin, into a 	 ner, R. C.; Kiick, K. L., Extracellular Matrix Structure, Func- 
polymer matrix allows for the exploitation of heparin's affin- 	 tion, and Applications to Tissue Engineering, CRC Biomedi- 
ity for growth factors as a strategy to deliver them from a 	 cal Engineering Handbook, CRC Press, New York, 2004; 
fibrous ECM-mimetic matrix. Those having skill in the art 35 Huang et al., Composites Science and Technology 2003, 63, 
understand that heparin binds a variety of proteins with dis- 	 2223-2253) (All said references are herein incorporated by 
parate function. It is contemplated that any such protein 	 reference in their entirety). A broad range of electrospun 
would be a candidate for use in this invention. 	 materials have been published and include synthetic poly- 
Method of Formulating Functionalized Polymers 	 mers with electrical properties ranging from non-conducting 
Some methods for processing polymers into a given form 40 polyurethane to conductingpolyaniline, in addition to natural 
that can be applied in the invention for producing polymeric 	 polymers such as collagen and silkworm silk. There is also 
matrices capable of controlled release of the compatibilizing 	 much recent work on nanofibers electrospun from biocom- 
polymer/biomolecule conjugates include, for example, 	 patible or biodegradable polymers for bioengineering appli- 
crosslinking of a polymer to form a hydrogel network can be 	 cations. The fibers may be made from a polymer solution via 
employed; any method for crosslinking polymers can be 45 an electro spinning process as described in Reneker, U.S. Pat. 
applied for formation of the crosslinked network, using stan- 	 No. 4,323,525, U.S. Pat. No. 4,689,525, US 20030195611, 
dard initiators or at least trifunctional monomers; standard 
	
US 20040018226, and US 20010045547, which are incorpo- 
free radical initiators include thermal initiators, redox initia- 	 rated herein by reference in their entirety. The specific types 
tors, photoinitiators; the inclusion of a bifunctional vinyl 	 of polymers that may be produced in fiber form via the elec- 
molecule with appropriate vinyl monomers would produce 50 trospinning process include those listed in Huang, US 
crosslinked networks of the vinyl matrix polymers. 	 20030195611, US 20040037813, US 20040038014, US 
Additionally, noncovalent methods of producing a 	 20040018226, US20040013873, US 2003021792, US 
crosslinked network could be employed. Such interactions 	 20030215624, US 20030195611, US 20030168756, US 
include but are not limited to ionic crosslinking (e.g. alginate 	 20030106294, US 20020175449, US20020100725 and 
crosslinking via interaction with divalent cations, layer-by-  55 US20020084178 all of which are herein incorporated by ref-
layer deposition of polyelectrolytes, etc.), protein-protein 	 erence in their entirety. 
interactions, peptide-saccharide interactions, saccharide-sac- 	 When constructing electrospun fibers forbiomedical appli- 
charide interactions, self-assembly of peptidic molecules, 	 cations, certain material considerations must be acknowl- 
and antibody-antigen interactions. The pore size of the 	 edged. Some minimal properties of a drug delivery system are 
crosslinked network should be smaller than the size of the 60 that the material must be non-immunogenic, degradable with 
compatibilizing polymer/biomolecule conjugate in order to 	 non-toxic products, able to be excreted from the body, and 
permit release of the biomolecule to be delayed via its con- 	 deliver therapeutic molecules in a controlled and predictable 
jugation to the compatibilizing polymer. 	 manner. Manufacturing time and complexity, along with han- 
Any method of forming different three-dimensional par- 	 dling, must also be considered. In compliance with these 
ticles and structures could also be applied in the current 65 requirements, matrix polymers such as PEO and PLGA serve 
invention. For example, emulsion (or inverse emulsion) poly- 	 as excellent candidates for fabrication of the matrix via elec- 
merizations, crosslinking (in colloidal suspensions, micellar 	 trospinning; indeed, the successful use of these polymers in a 
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variety of tissue engineering and drug delivery applications 
has been documented. Those having skill in the art are famil-
iar with the processes used in tissue engineering and drug 
delivery as required for incorporation in this invention. 
In addition to electrospinning, other traditional methods of 5 
making polymeric fibers can be applied, when possible, to the 
formation of active fibers of larger diameter. Given the choice 
of biomolecule or functional molecule or particle with a par-
ticular matrix polymer would dictate the use of solution spin-
ning, melt spinning, or other spinning protocols. 10 
Regarding the attachment of the biomolecule (or other 
small functioning molecules) to the compatibilizing polymer, 
the chemical reactions to be used are unlimited and are chosen 
based on the desired compatibilizing polymer/biomolecule 
combination. Initially, the matrix polymer composition may 15 
be altered for any given desired application and the combi-
nations of matrix polymer/compatibilizing polymer/biomol-
ecule for any application are limited only by the choice of a 
given application, not by the scope of the invention. 
In a preferred embodiment, poly(ethylene glycol) (PEG) 20 
functionalized with low molecular weight heparin (PEG-
LMWH), is fabricated into fibers for use in drug delivery, 
tissue engineering, or wound repair applications. In particu-
lar, a four-arm star PEG with covalently attached LMWH was 
found to be well suited for incorporation into electrospun 25 
fibers with matrix polymers such as PEO and PLGA. Further, 
the use of a PEG-LMWH conjugate proved to have a better 
effect on growth factor binding than when compared to free 
LMWH (see Example 1). 
Interestingly, it was observed that the incorporation of 30 
heparin into the electrospun PEO and PLGA fibers did not 
affect the surface morphology or fiber diameters. The fibers 
produced had diameters ranging from approximately 100 nm 
to 400 mu. Our data indicates that PEG-LMWH conjugates 
can be incorporated into an electrospun matrix at concentra- 35 
tions ranging from 3.5 µg to 85 µg per milligram of electro-
spun fibers, although with greater heparin concentrations in 
the spinning solution, it should be feasible to produce higher 
levels of heparin loading in the fibers. Incorporation of PEG- 
LMWH into the matrix permits retention of the heparin for at 40 
least 14 days. Improvements in the binding of basic fibroblast 
growth factor (bFGF) to the electrospun fibers were also 
observed for fibers functionalized with PEG-LMWH over 
those functionalized with LMWH alone. The combination of 
these results suggests the utility for producing electrospun 45 
fibers that are appropriately functionalized for use in bioma-
terials applications. 
Although LMWH was indicated to be incorporated into 
fibers with simple mixing in our investigation, the conjuga-
tion of LMWH to the star PEG slightly improved the amount 50 
of heparin incorporated into the fiber matrix and permitted a 
significantly improved amount of growth factor binding to 
these matrices, which was suggested to result from an 
improved retention of heparin in the fibers. If the use of such 
PEG-LMWH conjugates also slows the release of heparin 55 
over extended periods of time, it will allow for a slower, more 
sustained release of growth factor, which is often required to 
achieve desired biological outcomes. 
The conjugation of heparin, and more preferably, LMWH, 
to a relatively short (relative to the matrix polymer molecular 60 
weight) polymeric chain therefore permits facile functional-
ization of fibers and also allows for retention and significantly 
slowed release of LMWH from the matrix over time. Given 
the importance of co-presentation of the LMWH with growth 
factors at the growth factor receptor these systems also offer 65 
the potential advantage of improving growth factor activity 
over systems in which heparin is covalently attached directly 
to the matrix and can therefore not be co-released with growth 
factor. The rate of release of heparin (and therefore growth 
factors) may also be modified via modifications in the poly-
mer conjugate's molecular weight over a wide range, and 
coupled with the greater entanglement likely for flexible 
polymer chains, this may offer advantages over simple incor-
poration of a higher molecular weight heparin in fibers. In 
addition, the controlled incorporation and delivery of other 
and potentially smaller bioactive molecules, such as peptides, 
would also be widely possible via the incorporation of other 
similar PEG bioconjugates into these fibers. The ability to 
simply mix various PEG-conjugates in the electrospinning 
solution also offers advantages for creating multifunctional 
fibers. 
The PEG-LMWH molecules used in these electrospinning 
studies have previously been demonstrated to be capable of 
sequestering growth factors in hydrogels and delivering them 
in bioactive form to induce proliferation of human umbilical 
vein endothelial cells. The amount of LMWH in these elec-
trospun fiber matrices (3-86 µg) is also similar to that in 
hydrogels produced with these polymers; the hydrogels can 
effectively release bFGF for time periods of at least 16 days. 
These results therefore show significant promise for the 
potential of delivering similarly active growth factors from 
electrospun matrices. The additional advantage of the ease of 
mixing combinations of PEG-conjugates in the fibers is also 
promising for the facile production of multifunctional, non-
immunogenic matrices for biomaterial applications. 
It was found that LMWH functionalized PEG molecules 
can be easily incorporated into electrospun fibers. These 
fibers have nanometer scale diameters when electrospun 
using either PEO or PLGA as carrier polymers. The amount 
of LMWH per mg of fibers can range from 3.5-9.5 µg depend-
ing on the sample examined. Although both LMWH and 
PEG-LMWH can be processed into fibers, the incorporation 
of PEG-LMWH results in functional advantages such as 
improved growth factor binding, resulting from improve-
ments in retention of the PEG-LMWH in the fibers over the 
LMWH alone. The PEG-LMWH can be retained in the fibers 
for at least 14 days, in contrast to LMWH, which is almost 
completely released from the fibers after 24 hours. A slower 
release of LMWH, and any coupled growth factors, allows for 
drug delivery over a period of time that more closely matches 
the time scales needed for tissue repair or regeneration should 
the fibers be used in biomedical applications. The use of 
electrospinning as the fabrication method for this biologically 
functionalized matrix is preferred due to its ability to allow 
for the incorporation of LMWH, ease of fabrication, fiber 
spinning at a variety of temperatures, and use of small 
amounts of material. The ability to scale electrospinning from 
the laboratory to the industrial scale offers opportunities to 
produce matrices for biomaterials applications. The electro-
spun matrix also meets many requirements in its porosity and 
3-D nature to make the fibers suitable for drug targeting and 
tissue engineering applications. Such simple strategies for 
creating electrospun matrices that are both structurally rel-
evant and biologically active could find increased utility in a 
variety of biomedical applications. 
Functionalized Cross-Linked Matrices 
In an alternative embodiment, the invention is directed to 
the use of a functionalized compatibilizing polymer in the 
production of materials in which assembly, mechanical 
response, and biological properties are controlled by protein-
polysaccharide interactions. Such materials are designed to 
mimic the biological environment and find use in the delivery 
of growth factors. 
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Specifically, functionalized crosslinked matrices, such as 
hydrogels, capable of assembly by, for example, interactions 
between heparin and peptides, permit the formation of matri-
ces that allow for effective protein delivery. For example, an 
elastic or viscoelastic hydrogel formed by the combination of 5 
a compatibilizing polymer-LMWH conjugate and a compati-
bilizing polymer-peptide conjugate is a preferred interaction 
contemplated herein. While the use of any compatibilizing 
polymer is contemplated, a preferred compatibilizing poly-
mer for use in this embodiment would include PEG. Also, io 
while preferred, it is not necessary that the compatibilizing 
polymer be the same for both the LMWH conjugate and the 
peptide conjugate. 
In this particular embodiment, a hydrogel provides the 
benefits of controlling drug delivery rates by, for example, 15 
changing the heparin-binding peptide or manipulating the 
hydrogel's physical properties and erosion profiles. 
In a specifically preferred embodiment (more fully 
described in Example 4) a heparin-binding, coiled coil pep-
tide, PF4ZIP1  was employed to mediate the assembly of hep- 20 
arinized polymers. Heparin binding peptides (HBP) from 
antithrombin III and the heparin interacting protein have also 
been employed; any heparin-binding peptide with desired 
affinities can be used in the production of materials of this 
kind. Importantly, viscoelastic hydrogels were formed upon 25 
the association of PF 4ZIP-functionalized star poly(ethylene 
glycol) (PEG-PF4ZIP) with low-molecular-weight heparin-
functionalized star PEG (PEG-LMWH). The viscoelastic 
properties of the hydrogels can be altered via variations in the 
ratio of LMWH to PF 4ZIP (or any HBP). Comparison of 30 
growth factor (bFGF) release profiles with the hydrogel ero-
sion profiles indicates that bFGF delivery from this class of 
hydrogels is mainly an erosion-controlled process and the 
rates of bFGF release can be modulated via choice of HBP or 
via variations in the mechanical properties of the hydrogels. 35 
Manipulation of hydrogel physical properties and erosion 
profiles provides novel materials for controlled growth factor 
delivery and other biomedical applications. 
Growth Factor-Cross-Linked Matrices 
In even another alternative embodiment, the invention is 40 
directed to the use of a functionalized compatibilizing poly-
mer to form a crosslinked matrix that comprises the combi-
nation of a compatibilizing polymer-biomolecule conjugate 
and a growth factor, wherein a biomolecule such as LMWH 
functions effectively. In such an embodiment, it is intended 45 
that the growth factor function as a cross link that eventually 
is removed and drug is released. Removal of the growth factor 
may result from passive release and/or targeted release via 
targeted ligand exchange of the growth factor with specific 
receptors on cell surfaces. The growth factor crosslink may 50 
also itself be the desired drug, or in certain cases, the PEG-
LMWH polymer may have desired biological effect. 
In a specifically preferred embodiment, PEG-LMWH can 
be mixed with vascular endothelial growth factor (VEGF) to 
form a viscoelastic hydrogel. Formation of a hydrogel occurs 55 
as a result of the binding of the heparin-binding VEGF, with 
multiple heparin binding sites, to the PEG-LMWH. While 
VEGF, a dimeric growth factor with two heparin-binding 
sites, is described, other methods for generating growth fac-
tors with multiple heparin binding sites could produce a 60 
growth factor capable of crosslinking PEG-LMWH polymers 
via noncovalent interactions (e.g. genetic mutation of growth 
factor genes to introduce additional heparin-binding sites in 
the growth factor, conjugation of multiple growth factors to a 
polymer, etc.). Noncovalently crosslinked PEG-LMWH/ 65 
VEGF hydrogels are capable of releasing VEGF over periods 
spanning at least two weeks, and the release of VEGF (and 
16 
resulting erosion of the network) is also responsive to the 
presence of the cell surface receptors for VEGF. Release of 
VEGF, and erosion of the network, can therefore be coupled 
and made responsive to the cellular environment. VEGF 
released from such assemblies causes increased proliferation 
of porcine aortic endothelial (PAE) cells, which confirms that 
the released VEGF is bioactive. Release of other growth 
factors via similar mechanisms should therefore also be pos-
sible to permit release of multiple, bioactive growth factors. 
Although the invention is illustrated and described herein 
with reference to specific embodiments, the invention is not 
intended to be limited to the details shown. Rather, various 
modifications may be made in the details within the scope and 
range of equivalents of the claims and without departing from 
the invention. 
EXAMPLES 
Example 1 
Electrospinning Functionalized Fibers 
Materials and Methods 
Hydroxy terminated and thiol terminated four-arm star 
poly(ethylene glycol)s (Mn 10,300; Mw 11,300 g/mol and 
M„=10,000; M_-10,800 g/mol, respectively) were pur-
chased from Polymer Source (Dorval, QC, Canada). LMWH 
sodium salt (porcine intestinal mucosa, avg. molecular 
weight 3000 g/mol) was obtained from Sigma (St. Louis, 
Mo.). Alexa Fluor® 350 carboxylic acid, succinimidyl ester 
was obtained from Molecular Probes (Eugene, Oreg.). Sol-
vents and reagents were distilled or purified according to 
standard procedures. 
Synthesis of PEG-LMWH Conjugate 
N-Deacetylation of LMWH. 
LMWH (M, 3000 g/mol) was used in these investigations. 
In some cases, the LMWH was first separated into a high 
affinity fraction via anionic exchange chromatography on 
diethyl aminoethyl (DEAF) resin. Such fractionation is not an 
absolute requirement, but provides a LMWH fraction with 
higher heparin binding affinity. LMWH was eluted from the 
column via gradient elution in Tris buffer (pH 7.5, 20 mM) 
with sodium chloride concentrations ranging from 0 to 2M. 
The late eluting fraction of LMWH was collected, dialyzed 
against several changes of deionized water (SpectraPor, 
MWCO 1000 Da), and lyophilized prior to use. The fraction-
ated LMWH (250 mg), hydrazine (5.3 g), hydrazine sulfate 
(53 mg), and water (2.3 mL) were added to a heavy duty 
reaction vessel, and the reaction vessel was tightly capped and 
the mixture was stirred at 95° C. for 16 h. After the solvents 
were removed in vacuo, the product was dialyzed using a 
SpectraPor dialysis membrane (MWCO 1000 Da) first 
against 1 M NaCl and finally against water (for each dialysis 
bath was changed four times after 2, 8, 16, and 24 h) and 
lyophilized to afford a slightly yellowish solid, 153 mg (61% 
yield). 
Synthesis of Maleimide and Alexa Fluor 3508 Functional-
ized LMWH. 
To a 10 mL vial were added N-deacetylated heparin (10 
mg), dry dowex 50WX4-200 ion-exchange resin (strongly 
acidic cation), and anhydrous dimethylformamide (DMF, 4 
mL) and the reaction mixture was stirred at room temperature 
until complete dissolution of heparin was observed. The resin 
was filtered and to the filtrate were added a few drops of 
anhydrous triethylamine and a solution of 4-(N-maleimidom-
ethyl)cyclohexanecarboxylic acid N-hydroxysuccinimide 
ester (0.75 equiv.) (Sigma, St. Louis, Mo.) in anhydrous DMF 
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(0.3 mL) and the reaction mixture was stirred at 60° C. for 20 	 wavelength of 747 nun and a KP685 filter were employed for 
h. To this mixture was added a solution of Alexa Fluor 3508 	 these experiments. An oil immersion type Plan-Neofluar 40x/ 
carboxylic acid, succinimidyl ester (1 equiv.) in anhydrous 	 1.3 oil DIC (differential interference contrast) was used to 
DMF and the reaction mixture was further stirred at 60° C. for 	 obtain images in FIGS. 4, 5, 9,10,12 and a Plan-Apochromat 
20 h. The solvent was removed in vacuo to yield a slightly 5 63x/1.4 oil Ph3 (phase contract the 3 denotes a specific 
yellowish solid, which was redissolved in PBS (pH 6.5, 0.10 	 condenser lens used) was used to collect the image in FIG. 7. 
M, 0.15 M NaCI). After the insoluble particles were filtered, 	 A z-series was made for each sample at 0.8 or 1.0 µm sections. 
the filtrate was purified via fast protein liquid chromatogra- 	 Toluidine Blue Assays 
phy (FPLC) equipped with a Superdex 200 gel filtration col- 	 To determine the amount of heparin in the electrospun 
umn (Amersham, Piscataway, N.7.) using 0.2 M NaCl at 0.5 io fibers, a common colorimetric method employing toluidine 
mL/min as eluting buffer. The heparin containing fractions 	 blue was used. A toluidine blue solution was made by dis- 
were combined and dialyzed using a SpectraPor membrane 	 solving 25 mg toluidine blue (Sigma Aldrich, St. Louis, Mo.) 
(MWCO 1000 Da) first with 1 M NaCl and finally with water 	 and 1 g NaCl in 0.49 mL of 37% HCl and 50 mL of water. The 
(each dialysis bath was changed four times after 2, 8, 16, and 	 toluidine blue that reacts with the heparin is removed from 
24 h) and were then lyophilized to give a slightly yellowish 15 solution via extraction with hexanes (5 mL). The amount of 
solid, 4.2 mg; 'H NMR (400 MHz, D 20, 29° C.): d-0.86-1.95 	 unextracted toluidine blue remaining in the aqueous solution 
(10H, cyclohexyl, m), 3.38-5.43 (72H, heparin, m), and 6.84 	 was determined by measuring the absorbance at 631 nun and, 
ppm (2H, —COCH CHCO , s). 	 by difference, provides an estimate of the heparin concentra- 
Synthesis of PEG-LMWH. 	 tion. 
To a 100 mL round bottom flask equipped with a N 2 inlet 20 Samples were prepared by adding 1 mg of electrospun 
were added maleimide and dye-functionalized LMWH (120 	 fibers to a solution consisting of 0.8 mL of toluidine blue 
mg) and PBS (10 mL, pH 6.5, 0.10 M, 0.15 M NaCI) and the 	 solution and 2.5 mL of 0.1 % NaCl. The test tube was vortexed 
solution was degassed by bubbling N 2 for 15 min. To this 	 and 5 mL of hexanes was added with additional vortexing. 
solution was slowly added a degassed solution of PBS con- 	 After 10 minutes, 1201 qL of the toluidine blue solution was 
taining thiol terminated four-arm star PEG (65 mg in 10 mL) 25 transferred into a cuvette and absorbance measurements were 
and the reaction mixture was stirred at room temperature for 	 taken. The control samples consisted of 1 mg of either PEO or 
2 h. The reaction of the thiol was 96% complete as confirmed 
	
PLGA fibers, without heparin, to adjust for the amount of 
via analysis with Ellman's reagent. The reaction mixture was 	 toluidine blue that may adhere to the fibers. Measurements 
quenched by adding a solution of N-ethylmaleimide (12 mg) 	 were performed in duplicate. 
in DMF (0.4 mL). The crude product was purified via FPLC 30 Growth Factor Binding 
with a Superdex 200 gel filtration column (Amersham, Pis- 	 Growth factor binding assays were employed to determine 
cataway, N.7.) at 0.5 mL/min using 0.2 M NaCl as eluting 	 if the LMWH and PEG-LMWH electrospun samples were 
buffer. Theproduct isolated by FPLC was purified via dialysis 	 able to bind bFGF. All growth factor experiments were com- 
against water (water bath was changed four times after 2, 8, 	 pleted at room temperature in 24-well polystyrene assay 
16, and 24 h) and lyophilized to give a slightly yellowish 35 plates (Coming Inc., Coming, N.Y.), blocked with 3% bovine 
solid, 150 mg; i H NMR (400 MHz, D 20, 29° C.): d-0.86- 	 serum albumin (BSA) (Sigma Aldrich, St. Louis, Mo.) in 
1.95 	 (40H, 	 cyclohexyl, 	 m), 	 2.50-2.88 	 (12H, 	 phosphate buffered saline (PBS) (Invitrogen, Carlsbad, 
	
COCH2CHC0 , m), 3.38-5.43 (288H, heparin, m), and 	 Calif.). All electrospun samples were washed with PBS at 
3.70 ppm (908H, PEG backbone, CH 2CH20 , s). Inte- 	 room temperature. Samples were placed in the wells and 
gration of the i H NMR spectrum suggests 73% functional-  40 incubated with 500 µL of a solution of basic fibroblast growth 
ization of PEG with LMWH. 	 factor (bFGF, R&D Systems, Minneapolis, Minn., 10 ng/mL 
Electrospinning and Characterization 	 in PBS) for 2 h. After seven washes with 0.05 wt % Tween20 
Fiber Spinning 	 in PBS (PBS-T), 500 µL of a solution of bFGF antibody was 
	
The electrospinning apparatus consisted of a syringe pump 	 added (R&D Systems, Minneapolis, Minn., 2 µg/mL in PBS) 
(Orion SageTM, Fisher, Fair Lawn, N.7.), high voltage supply 45 and incubated for 2 h. The samples were washed seven more 
(Glassman Series EH, High Bridge, N.7.), 1 mL syringe (Pop- 	 times with PBS-T. The samples were then incubated for 30 
per & Sons, New Hyde Park, N.Y.) and a needle (Hamilton, 	 min. in a 500 µL solution consisting of 1 µL horseradish 
Reno, Nev.) with an inner diameter of 0.51 mm. A voltage of 	 peroxidase conjugated NeutrAvidin (Pierce, Rockford, Ill., 1 
—12 kV was applied to the tip of the needle. A grounded metal 	 mg/mL), 8 mL PBS, and 2 mL SuperBlockTM Blocking 
sheet was used as the target and was positioned 15 cm from 5o Buffer (Pierce, Rockford, Ill.). The fibers were then washed 
the tip of the needle for sample collection. The concentration 	 seven times with PBS-T and incubated in 500 µL of TMB 
of the polymeric solutions varied depending on the carrier 	 substrate solution (Pierce, Rockford, Ill.) for 10-12 mins. 
polymer employed. PEO (BDH Chemicals, Poole, UK, 	 Absorbance at 450 nm was measured. All absorbance values 
M_-300,000 g/mol) was used at a 10 wt % concentration in 	 were normalized with respect to a well treated withbFGF and 
water and a flow rate of 0.07 mL/min was employed. PLGA 55 antibody, as explained previously, but without any electro- 
(Sigma Aldrich, St. Louis, Mo., 75:25, M_-90,000-126,000 	 spun fibers. The growth factor binding assay was completed 
g/mol) solutions were made at a 45 wt % concentration in 	 three times and the average values are reported. 
DMF (Fisher, Fair Lawn, N.7.) andrequired a flow rate of 0.26 	 Results 
mL/hr. 	 Electrospinning Physical Mixtures (1:4) of LMWH and PEO 
Characterization 	 60 A 1:4 LMWH to PEO mixture (25 mg LMWH and 100 mg 
	
The electrospun fibers were characterized via field emis- 	 PEO) was dissolved in water and electrospun. The fibers 
sion scanning electron microscopy (FESEM) (Hitachi 	 resembled typical electrospun PEO fibers with an approxi- 
5-4700) coupled with the energy dispersive X-ray (EDX) 	 mate diameter of 100-400 nm and were slightly beaded. The 
(Oxford Inca X-Ray Microanalysis) for elemental analysis of 	 presence of microspheres with an average diameter of 1-5 µm 
electrospun fibers. Laser scanning confocal microscopy, 65 was also observed. Two control solutions were made. One 
LSCM, (Zeiss LSM 510 NLO) was used to observe the loca- 	 control consisted of a 10 wt % PEO/H 2O and the other a 10 wt 
tion of the heparin-bound dye. A fluorescence excitation 	 % LMWH/H 2O. The 10 wt % PEO/H 2O solution electrospun 
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to form PEO fibers with a diameter of 100-400 mu. The fibers 
were circular in their shape and contained beads (200-600 nm 
in diameter) but no microspheres were observed. The 10 wt % 
LMWH/H20 control did not form fibers or microspheres, 
which is almost certainly due to the lack of entanglements in 5 
the negatively charged LMWH (3,000 g/mol). Attempts to 
electrospin higher MW heparin (12,000 g/mol) also failed for 
similar reasons. 
Toluidine blue assays were performed on the electrospun 
physical mixtures of PEO and LMWH to determine if 10 
LMWH was present in the sample. It was found that 86 qg 
(+/-7.15) of LMWH was present per mg of electrospun 
fibers. The presence of LMWH indicated by the toluidine 
blue assav is consistent with the nresence of LMWH in the 
15 
matrix. 
EDX was employed to determine the location of the hep-
arin in the fiber matrix via detection of sulfur on the sulfated 
heparin; the results of the EDX analysis are outlined in Table 
1. The presence of aluminum in the sample is due to the 20 
aluminum SEM mount used to hold the fibers. PEO fibers 
served as a control for this experiment; EDX detected 46% C, 
5% 0, and 49% Al in the PEO fibers, consistent with the 
composition of PEO. The significant amount of C detected 
was most likely to due to carbon adhesive tab that was used to 25 
secure the fibers for imaging. A thin film was cast of 10 wt % 
LMWH/H20 and used as the second control The atomic 
composition detected via EDX was 23% C, 40% O, 17% S, 
and 18% Na, consistent with the presence of LMWH in the 
sample (sodium is the counterion for the LMWH used in these 30 
studies). The 1:4 LMWH:PEO electrospun sample was tested 
in three different areas: the fiberportion, beadportion, and the 
microsphere. The fibers contained 42% C, 5% O, and 59% Al. 
Since no sulfur or sodium was detected, the results suggest 
that either the fiber section of the matrix consists of primarily 35 
PEO or that the concentration of sulfur is too low for detection 
via EDX. Generally, the lower limit of detection for EDX is 
approximately 1%, so it is possible that the LMWH may be 
incorporated into the fibers but at a concentration much lower 
than 1%. The beaded section of the matrix was found to 40 
contain 61% C, 13% O, 26%Al, and 0.3% S. The detection of 
the sulfur indicates that LMWH is present, at low concentra-
tions, in the beaded areas of the electrospun mat. The micro-
spheres were shown to contain 73% C, 20% O, 4% Al, 1.2% 
S, and 1.4% Na. The presence of sulfur and sodium imply that 45 
LMWH is present in the microspheres at higher concentra-
tions than found in the beaded sections of the mat. The EDX 
results are consistent with the expected composition of the 
fibers, and the varying amount of sulfur in the different 
regions suggests that LMWH is not uniformly incorporated 
into the fibers via simple mixing. 
TABLE 1  
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Electrospinning Dye-Labeled LMWH with PEO 
To visually map the location of the LMWH throughout the 
electrospun mat, a fluorescent dye, Alexa Fluor 3508, was 
covalently attached to LMWH, and the fibers were analyzed 
via LSCM; observation of fluorescence permits direct obser-
vation of the presence and location of LMWH throughout the 
electrospun matrix. PEO (10 wt %) was mixed with Alexa 
Fluor 350®-labeled LMWH (0.2 wt %) and electrospun. FIG. 
1 shows resulting fibers with diameters of approximately 
100-200 mu, with a few very large beads approximately 6 µm 
in diameter. 
The fibers were then analyzed via LSCM to determine if 
the LMWH-dye molecules were incorporated into the matrix 
and to determine their distribution in the matrix. Electrospun 
PEO fibers were used as a control; results for the control are 
shown in FIG. 2. FIG. 2a shows data in reflection mode and 
confirms that fibers were present on the glass coverslip. FIG. 
2b shows two small areas of fluorescence that are likely 
impurities in the PEO or dust in the sample, but confirms the 
complete lack of background fluorescence in the PEO fibers. 
FIG. 3 presents LSCM data for electrospun fibers of the 
LMWH-dye/PEO mixture. The results demonstrate the fluo-
rescence of the fibers, indicating the presence of LMWH. In 
contrast to SEM and EDX results, the LSCM results also 
suggest that the LMWH-dye is present not only in the beaded 
sections of the matrix, but also in the fiber regions. FIG. 3 
shows the fluorescence of the fibers due to LMWH-dye incor-
poration. Z-stack images were also taken (not shown) to 
ensure that the LMWH-dye is present throughout the entire 
depth of the matrix and is not localized in any one area. Due 
to the LSCM limit of resolution, approximately 200 mu, the 
exact location of the heparin within each individual fiber is 
unknown. However, all LSCM images indicate that LMWH 
is present throughout the depths of the electrospun matrix, 
suggesting a fairly uniform dispersion of LMWH. Measure-
ment of LMWH via toluidine blue assay confirmed the pres-
ence of approximately 4.3 ltg (+/-0.923) of LMWH per mg of 
electrospun sample. A direct comparison cannot be made 
between the amount of LMWH in this sample and the amount 
in the physical mixtures of LMWH and PEO due to differing 
amounts of LMWH in the initial solutions. Nevertheless, 
these results suggest the opportunities for facile incorporation 
of bioactive polysaccharides into electrospun matrices. 
Incorporation of PEG-LMWH-Dye in PEO for Electrospin-
ning 
LMWH was covalently attached to the termini of a 4-arm 
star PEG and evaluated for its incorporation into an electro-
spun matrix. PEG-LMWH-dye (0.2 wt %) was mixed with 
PEO (10 wt %) in water. The electrospun fibers from this 
solution were analyzed via FESEM, with results shown in 
Average elemental composition of electrospun samples as 
determined by EDX (compositions are represented in atomic weight percent) 
Sample 	 C (i) 	 0(%) 	 At (i) 	 S(%) 	 Na (i) 
PEO Fibers 	 46±14.7 5.0±1.15 	 49±14.2 	 ND* 	 ND 
LMWH Film 	 23±1.63 	 40±2.16 	 ND 	 17±1.41 	 18±2.50 
1:4 LMWH:PEO 
fiber section: 	 42 ± 9.02 5.0 ± 0.577 	 59 ± 18.9 	 ND 	 ND 
bead section: 	 61 ± 2.65 	 13 ± 2.31 	 26 ± 4.51 	 0.3 ± 0.025 	 ND 
microsphere section: 73 ± 2.52 	 20 ± 5.13 	 4.0 ± 1.66 	 1.2 ± 0.48 	 1.4 ± 0.13 
*ND = not detected 
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FIG. 6. As is shown in FIG. 6, the resulting fibers were 	 Carlsbad, Calif.) overnight. All samples were washed three 
100-300 mu in diameter with the presence of microspheres 	 times with PBS at room temperature and then incubated with 
(1-3 µm). The morphology of the PEG-LMWH fibers was 	 4 µL bFGF (R&D Systems, Minneapolis, Minn., 2.5 µg/mL in 
very similar to those produced from the earlier samples with 
	
PBS) for 2 h at 4° C. The fibers were then transferred to the 
free LMWH. In both electrospun mats, fibers are in the 5 transwell membrane and 1 mL of PBS was added and incu- 
nanometer size range and the onset of bead formation is 	 bated at 4° C., unless otherwise indicated, for a specified 
observed by the roughness of the fibers (see FIGS. 1 and 4). 	 amount of time. The wells were replenished with fresh PBS 
The fiber matrix was then analyzed via LSCM to confirm 	 after each aliquot was removed. The amount of bFGF present 
that the PEG-LMWH-dye molecule was incorporated in the 	 in the matrix was determined via use of a standard spectro- 
electrospun fibers; representative results are shown in FIG. 5. io photometric immunochemical assay following the protocols 
Similar to the results in FIG. 3, the data shown here also 	 of the manufacturer (R&D Systems, Minneapolis, Minn.). 
indicate that the fibers are evenly fluorescent across the 	 Slight variations of the procedure could be necessary depend- 
matrix, showing that the PEG-LMWH was evenly distributed 
	 ing on the composition of the matrix. 
in the PEO fiber matrix. These fibers were found to contain 	 The optical density measurements, at a wavelength of 450 
3.5 µg (+/-0.397) of heparin per mg of electrospun fibers. 15 mu, resulted in the following absorbance values relative to the 
These results indicate a slight improvement in LMWH incor- 	 control (increasing absorbance values correlate with increas- 
poration in comparison to the LMWH/PEO fibers, and may 	 ing growth factor binding): PLGA fibers 1.59 (+1-0.055), 
suggest that PEG-LMWH permits the incorporation of 
	
LMWH/PLGA fibers 2.46 (+/-0.146), and PEG-LMWH/ 
slightly more heparin than in the fibers produced using free 	 PLGA fibers 3.59 (+/-0.106). FIG. 9 shows that there are 
heparin. 	 20 significant differences in bFGF binding between the LMWH/ 
Changing the Matrix Polymer 	 PLGA and PEG-LMWH/PLGA fibers, despite the fact that 
Multiple polymers could be used as the matrix polymer. 	 the toluidine blue assays show that the two matrices contain 
PLGA was chosen as an alternate carrier polymer for the 	 similar amounts of LMWH after electrospinning. Since both 
LMWH systems due to the success of PLGA in biomaterial 
	
the LMWH and PEG-LMWH samples began with similar 
applications. PLGA/DMF (45 wt %) was electrospun with 25 amounts of heparin but did not exhibit the same level of bFGF 
LMWH-dye (0.2 wt %) and also with PEG-LMWH-dye (0.2 	 binding, these data suggest that the PEG-LMWH may be 
wt %). Due to differences in molecular weight and viscosity, 	 retained in the electrospun fibers more effectively than 
the concentration of carrier polymer is different than those 	 LMWH alone. FESEM characterization of the electrospun 
used for PEO electro spinning, but all other processing con- 	 membranes after the growth factor binding assay revealed 
ditions remained the same. The electrospun PLGA fibers are 30 that the PLGA fibers exhibited no visible signs of degradation 
approximately 400-800 nm in diameter, (FIG. 6a). SEM 	 during the time frame of the growth factor binding study 
revealed that fiber morphology was not affected by the incor- 	 (FIG. 10, parts a and b). This observation corroborates the fact 
poration of LMWH-dye or PEG-LMWH-dye, (FIGS. 6b and 	 that differences in growth factor binding likely result from 
6c). 	 differential LMWH retention rather than from variations in 
LSCM showed that the PLGA electrospun mat, shown in 35 fiber degradation between samples. These electrospun mem- 
FIG. 7a under transmitted light, does not fluoresce to any 	 branes were also incubated in PBS for an additional 1 day, 3 
significant extent. As encountered previously with PEO 
	 days, and 14 days to determine if any fiber degradation 
fibers, there is a small area of fluorescence in FIG. 7b, which 	 occurred (FIG. 10, parts c-h). These SEM images show that 
is likely due to polymer impurities or dust on the sample. The 	 there are no visible signs of fiber degradation for the time 
images shown in FIG. 8 reveal that both LMWH-dye and 40 period studied in this investigation. 
PEG-LMWH-dye were incorporated into the PLGA matrix 	 Characterization of the fibers after completion of the 
and z-stack LSCM images confirm that the heparin is present 	 growth factor binding assays was conducted via multiphoton 
throughout the depths of the matrices. The toluidine blue 	 microscopy. FIG. 11, parts a and b, shows the LMWH reten- 
assay indicated that there is approximately 8.41 µg (+/- 	 tion within the electrospun fibers after the growth factor 
0.532) of LMWH present per mg of electrospun LMWH/ 45 assay, or 6 h of PBS incubation. After only 6 h in PBS, slight 
PLGA sample. The PEG-LMWH/PLGA sample contained 
	 differences in the amount of LMWH within the fibers were 
9.50 µg (+/-0.382) of LMWH per mg of electrospun fibers. 	 observed via multiphoton microscopy; these differences were 
The results of the FESEM, LSCM, and the toluidine blue 	 much more pronounced with an additional 24 h incubation in 
assays suggest that the carrier polymer can be changed with- 	 PBS (FIG. 11, parts c and d). In FIG. 11, parts e-h, the 
out affecting the incorporation of heparin or fiber morphol-  50 multiphoton images are shown in fluorescence and reflection 
ogy. 	 mode. This was necessary due to the small amount of fluo- 
rescence in the samples in order to prove that fibers are 
Example 2 	 present. In FIG. 11, parts g and h, the most visible differences 
are observed. After 14 days incubation in PBS, the PEG- 
Growth Factor Release Assays of Electrospun Fibers 	 55 LMWH-dye fibers still exhibit a moderate level of fluores- 
cence in comparison to the LMWH-dye fibers, which show 
An ELISA format was employed to characterize the bind- 	 minimal signs of fluorescence. The differences in the amount 
ing of bFGF in a series of samples: a blank well, PLGA fibers 	 of LMWH retained in the fibers were also observed through- 
alone, LMWH/PLGA fibers, and PEG-LMWH/PLGA fibers. 	 out the depth of the matrix, as confirmed via z-stack images 
Growth factor release studies were performed using a Quan-  60 (see FIG. 12 for a representative z-stack image of PEG-
tikine Human FGF Basic Kit (R&D Systems, Minneapolis, 	 LMWH-dye fibers after 14 days incubation in PBS). 
Minn.). Incubation of the growth factor was completed using 	 bFGF release experiments were conducted with the 0.2 wt 
a 24-well polystyrene plate (Corning Inc., Corning, N.Y.) and 	 % LMWH-dye and PEG-LMWH-dye fibers over a 24 h 
transwell membranes (Fisher Scientific, Atlanta, Ga., 8 µm 	 period. As seen in FIG. 13, the release of LMWH-dye, PEG- 
pore size) were used to secure the fibers during the release 65 LMWH-dye, and the PLGA control all exhibited less than I% 
study. The plate, membranes, and fibers were blocked with 	 release of bFGF. This study was repeated to monitor the 
3% BSA (Sigma Aldrich, St. Louis, Mo.) in PBS (Invitrogen, 	 release over a 21 day period, assuming that the low release 
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rates were due to the short incubation time of 24 h. However, 	 using a syto 13 stain) on electrospun LMWH or PEG-LMWH 
the 21 day release consistently showed less than 1% bFGF 
	
fibers (fluorescing blue due to the dye attached to the hep- 
release for all samples. Similar results were obtained in 	 arin). FIG. 16b shows that more cells are present on the 
release studies conducted at 37° C. In order to determine if 
	
PEG-LMWH/PLGA matrix and the image suggests that more 
any bFGF remained in the electrospun matrices after these 5 cells penetrate the PEG-LMWH matrix (FIG. 16b) when 
release studies, a binding study was completed on the 0.2 wt 	 compared to the LMWH fibers alone (FIG. 16a). These 
% heparin-containing fibers after 5 h and 24 h release in PBS. 	 images illustrate the differences in cellular proliferation due 
FIG. 14 is a digital picture showing the visual differences in 	 to the presence of PEG-LMWH. Based on the results of this 
the binding of bFGF to the fibers. The more intense the blue 	 cellular assay it is believed that PEG-LMWH increases the 
color, the more bFGF present. This picture clearly shows 10 rate of cell proliferation in comparison to the other samples 
dramatic differences in binding to the PEG-LMWH fibers 	 due to the retention of PEG-LMWH in the matrix that causes 
versus LMWH and PLGA only fibers. However, more 	 increased retention and slower release of bFGF, which has 
LMWH is present in the PEG-LMWH-dye fibers. This sug- 	 been suggested in previous results presented in FIG. 14. The 
gests that either 1) more bFGF is retained in the PEG- 	 increased retention of bFGF may support higher cell prolif- 
LMWH-dye fibers due to the reduced diffusion times of the 15 eration rates. Although this was a very preliminary cell study, 
PEG-LMWH-dye complex or 2) all fibers may contain simi- 	 it does indicate that there are functional differences between 
lar amounts of residual bFGF but the PEG-LMWH-dye fibers 	 electrospun matrices functionalized with either PEG-LMWH 
protect the structure of the bFGF and, thus, apparently more 	 or LMWH alone. 
growth factor is detected by the immunochemical assay. 
20 	 Example 4 
Example 3 
Functionalized Cross-Linked Matrices 
Cell Proliferation Assay 
Materials 
The PEG-LMWH/PLGA, LMWH/PLGA, and PLGA 25 All materials were obtained and purified as described in 
fiber matrices were tested to determine if there were any 	 Example 1. 
differences in the ability of the membranes to affect cellular 	 Methods 
proliferation of MG63 (human osteosarcoma) cells. PLGA, 	 Synthesis of PEG-LMWH Conjugates 
LMWH/PLGA, and PEG-LMWH/PLGA electrospun mem- 	 The synthesis of the PEG-LMWH conjugate exploited in 
branes were sterilized under UV light for 4 h and incubated in 3o hydrogel assembly was conducted via Michael-type addition 
1.5 mL Dulbecco's Modified Eagle Medium (DMEM) con- 	 reactions between maleimide functionalized heparin and 
taining 5% (v/v) fetal calf serum (FCS), bFGF (10 ng/mL), 	 thiol -terminated four-arm star PEG, as described in Example 
penicillin (100 U/mL) and streptomycin sulfate (100 µg/mL) 	 1. The degree of LMWH functionalization in PEG-LMWH 
for 2 h. The membranes were then washed 2-3 times with 	 was determined to be 81% via i H NMR spectroscopy. Syn- 
sterile PBS. All membranes were incubated in bFGF (15 35 thesis of PEG-LMWH-Alexa Fluor 350 was conducted via 
ng/membrane) prior to the cell proliferation assay. The mem- 	 similar protocols as previously described in the art. 
branes were then placed in 24-well tissue culture dishes con- 	 Synthesis of PEG-HBP Conjugates 
taining an MG63 cell (2x105 cells/mL, American Type Cul- 	 All HBPs were prepared on Rink Amide MBHA resin via 
ture Collection, Manassas, Va.) suspension in DMEM 	 solid phase peptide synthesis with Fmoc-protection using a 
supplemented with 5% (v/v) FCS. The plates were shaken 40 PTI PS3 peptide synthesizer (Protein Technologies Inc, Tuc- 
every 30 min for 4 h. The scaffolds were then transferred to a 	 son, Ariz.) and purified via preparative-scale reverse-phase 
new 24-well plate and incubated in DMEM containing 1% 
	
HPLC. The PF4ZIP sequence CGGRMKQLED- 
(v/v) FCS at 37° C. in an atmosphere of 95% air and 5% CO 2 . 	 KVKKLLKKNYHLENEVARLKKLVG is based on a GCN 4 
Culture medium containing 1 % (v/v) FCS was changed every 	 coiled coil and mimics the heparin-binding domain of human 
3 days. Cultures were terminated on days 1, 3, 6, 9, 12, and 15. 45 platelet factor 4. The heparin-binding peptides, ATIII and 
MG63 proliferation was determined by immunodetection of 
	
HIP, from antithrombin III (ATIII) and heparin interacting 
bromodeoxyuridine (BrdU) incorporation (Cell Proliferation 	 protein (HIP), have sequences of CKbAFAKLAARLYRKA 
ELISA Biotrak System, Amersham Biosciences, Piscataway, 	 and CRPKAKAKAKAKDQTK, respectively. Any heparin- 
N.7.), according to the manufacturer's instructions. Cells 	 binding peptide of sufficient affinity and appropriately slow 
seeded on the electrospun membranes were labeled with 5o dissociation (from heparin) would be equally applicable for 
BrdU and then incubated with peroxidase-labeled anti-BrdU 	 use in these hydrogels. Peptides isolated as single fractions 
antibody. Excess anti-BrdU antibody was removed by wash- 	 via HPLC were characterized via MALDI and ESI mass 
ing the membranes with washing buffer in a vortex mixer. The 	 spectrometry. The mass of the purified HBPs was confirmed 
membranes were then incubated in TMB substrate to produce 	 via ESI mass spectrometry. For example, for PF 4ZIP1  
a colored solution. A plate reader was employed with detec-  55 m/z=992.5 [(M+4H)4+, calc'd 992.0] and m/z1322.9 [(M+ 
tion at 450 nm to obtain optical density measurements. Three 	 3H)3+, calc'd 1322.7]. Similar agreement between theoreti- 
fiber membranes per sample were tested each day. 	 cal and observed mass values was observed for all other 
FIG. 15 illustrates the differences in cellular proliferation 	 HBPs. 
on PLGA, LMWH/PLGA, and PEG-LMWH/PLGA mem- 	 The synthesis of the PEG-HBP conjugates utilized in 
branes. It was expected that cell proliferation would occur on 6o hydrogel assembly was conducted via Michael additionreac- 
all the samples tested due to the biocompatibility of PLGA, 	 tions between vinyl sulfone-terminated four-arm PEG and 
however, our interest was to determine which samples 	 cysteine-terminated PF4ZIP peptide. 
reached maximum cell proliferation first. The most signifi- 	 Characterization 
cant differences were observed on day 6 where PEG-LMWH 
	
Peptides, PEG-LMWH, and PEG-HBPs were character- 
membranes exhibit significantly higher cell proliferation and 65 izedvia 1 H NMR spectroscopy and MALDI-TOF Mass Spec- 
therefore reached saturation before LMWH/PLGA or PLGA 	 trometry to determine purity, composition, and degree of 
alone. FIG. 16 shows LSCM images of the cells (dyed green 	 functionalization. 
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Circular Dichroic Spectroscopy (CD) 	 solutions were mixed in ligand mole ratios of 9:0.5, 8:1, and 
CD spectra were measured at 5° C. to 75° C. on a 7asco 	 7.5:2.5 (LMWH:PF4ZIP dimer); other ligand mole ratios are 
7-810 spectropolarimeter (7asco Inc, Easton, Md.) equipped 	 also useful for hydrogel assembly. For VEGF-crosslinked 
with a 7asco PTC-424S temperature controller. Samples were 	 hydrogels, an 8 wt % solution of PEG-LMWH in PBS is 
equilibrated at the desired temperature for 30 minutes prior to 5 mixed with varying amounts of solid VEGF (0.1-20 qg) to 
data collection; equilibration was indicated by the absence of 	 afford a self-supporting gel upon sufficient addition of VEGF. 
further changes in the CD signal at longer equilibration times. 	 After mixing, the hydrogels were stored at 4° C. The stored 
All CD spectra were taken in a 1 mm path length quartz 	 hydrogels were equilibrated to room temperature prior to 
cuvette, at wavelengths from 200 to 250 mu. Data points were 	 theological characterization (typically several minutes). 
recorded at every nanometer with a 4.0 response time. The io bFGF Release and Hydrogel Erosion Experiments 
concentrations of peptide samples were determined via 	 bFGF release and hydrogel erosion experiments were per- 
amino acid analysis for calculation of mean residue elliptici- 	 formed at 4° C. in 24-well polystyrene assay plates (Corning 
ties. 	 Inc., Corning, N.Y.), blocked with PBS containing 5% BSA 
Heparin Affinity Measurements 	 and 0.05% Tween 20 (Sigma, St. Louis, Mo.). The wells were 
Heparin-sepharose affinity liquid chromatography was 15 aspirated and washed 4 times with 0.05% Tween 20 in PBS 
performed on an AKTA Explorer FPLC equipped with a 	 before loading samples. Afterward, 200 µL hydrogel was 
HiTrap Heparin HP column (5 ml, -10 mg heparin/ml gel, 	 placed on the bottom of each well and 2.8 mL PBS was added 
Amersham Biosciences Corp, Piscataway, N.7.). Surface 	 carefully over each gel. 1 mL PBS was taken out of the well 
Plasmon Resonance (SPR). SPR sensorgrams were recorded 	 at 1, 2, 6 and 24 h and then each following day, followed by 
on a BiaCore 3000 instrument (Biacore Inc, Piscataway, 20 replacement with 1 mL fresh PBS. The amount of bFGF in 
N.7.), employing a high-capacity LMWH surface created on 	 each sample was measured with a bFGF Quantikine kit (R&D 
a commercially available streptavidin-coated chip via treat- 	 Systems, Minneapolis, Minn.). Thehydrogel erosionkinetics 
ment with biotinylated LMWH. 	 were conducted on the same samples used for bFGF release 
Bulk Rheology Experiments 	 experiments. 
Bulk theology experiments of the PEG-LMWH/PEG-  25 Results 
HBP hydrogels were conducted at 25 or 37° C. on a stress- 	 Oligomerization of PF 4ZIP 
controlled rheometer (MCR 500, Paar Physica, Anton-Paar, 	 Our initial studies were aimed at determining the oligomer- 
Ashland, Va.) with a 25.0 mm diameter parallel plate geom- 	 ization properties of the coiled-coil PF 4ZIP, as such informa- 
etry and a 1 mm gap distance. Strain sweeps were performed 	 tion is relevant to the subsequent use of the PF 4ZIP in hydro- 
on samples from 0.001% to a maximum strain of 100% to 30 gel formation. No such characterization was necessary forthe 
determine the limit of the linear viscoelastic regime (LVE). At 	 other HBPs, as they do not form higher-order assemblies. 
a constant strain of 0.1%, chosen from the LVE, frequency 	 Circular dichroic spectroscopy studies were conducted to 
sweeps ranging from 0.1 Hz to 100 Hz were conducted. Shear 	 assess the folding of the PF 4ZIP under various conditions. 
recovery experiments were also performed for the PEG- 	 Solutions of PF4ZIP dissolved in PBS were scanned from 250 
PF4ZIP-containing hydrogels, and prior to these experiments, 35 nm to 200 nm at varying temperatures between 5° C. and 75° 
a baseline oscillation at a constant strain of 0.1% and a con- 	 C. The CD spectra of PF 4ZIP at a variety of temperatures 
stant frequency of 10 Hz was performed, followed by a high- 	 show an isodichroic point at 203 mu, validating the existence 
speed rotation with a 1000 s-1 shear rate for 10 s. The recov- 	 of a two-state equilibrium. At temperatures below 55° C., the 
ery was then measured with a time sweep experiment at a 	 spectra observed exhibit two minima at 208 mn and 222 mu, 
constant strain of 0.1% and a constant frequency of 10 Hz. 4o demonstrating that PF 4ZIP exists in the coiled-coil state 
Fluorimetry Experiments 	 under conditions of interest for hydrogel applications. As 
Fluorimetry experiments to measure the concentration of 	 seen by the appearance of a single minimum at 203 mn in the 
PEG-LMWH-Alexa Fluor 350 (in eroded solutions of PEG- 	 data collected at elevated temperatures, the structure of 
PF4ZIP-containing hydrogels) were performed using a Fluo- 	 PF4ZIP reversibly changes to random coil at elevated tem- 
roMax-3 spectrofluorometer (7obin Yvon Inc, Edison, N.7.) 45 perature. Maximum mean residue ellipticity values at 222 mn 
with a xenon arc lamp illuminator. Erosion of PEG-LMWH 
	 (MRE222) were measured to be -30,470 deg cm 2 dmol-i for 
from other PEG-HBP-containing hydrogels was determined 	 the PF4ZIP at 15' C., consistent with reported values ranging 
gravimetrically. 45 µL of each sample were loaded into a 	 from -25,000 to -35,000 deg cm 2 dmol-i for various GCN4- 
cuvette and excited at 346 mu, the excitation spectra peak 	 mimic peptides in PBS at 15° C. 
value ofAlexa Fluor 350. The emission spectra peak value at 50 	 The conformation of PF4ZIP at various concentrations was 
442 mn was recorded. Solutions of PEG-LMWH-Alexa Fluor 	 also monitored via CD. At all measured concentrations, the 
350 in PBS, with concentrations from 5.42x10-4 wt % to 	 spectra observed exhibit two minima at 208 mn and 222 mu, 
4.23x10-6 wt %, were employed for generation of the stan- 	 demonstrating the helical character of PF 4ZIP under these 
dard curve. For erosion profile experiments, the PEG- 	 conditions. The measured MRE222 for a solution of 56 µM 
LMWH-Alexa Fluor 350 was premixed with the PEG-  55 PF4ZIP in PBS is -24,580 deg cm2 dmol-1 , which is consis- 
LMWH at a weight ratio of 1:158. The fluorescence 	 tent with the value reported for 40-60 µM PF 4ZIP in 3 mM 
intensities of the PEG-LMWH-Alexa Fluor 350 in the eroded 	 sodium citrate buffer (-27,000 deg cm 2 dmol-i). The differ- 
PEG-LMWH were then measured and permitted calculation 	 ence between the measured ellipticity and the ellipticity of the 
of the percentage of PEG-LMWH eroded from the hydrogels 	 unfolded monomer is related to concentration and can be fit to 
in hydrogel erosion experiments. 	 6o determine the Kd of the dimerization, via standard fitting 
Assembly of PEG-LMWH/PEG-HBP (and PEG-LMWH/ 	 procedures well-described in the literature. The calculated 
GF) Hydrogels 	 equilibrium constant of unfolding, Kd, is 3.48±0.03 µM. 
The PEG-LMWH/PEG-HBP hydrogels were formed by 	 Solutions of PF4ZIP attached to star-PEG were also studied 
the interaction between LMWH and PF4ZIP. 5 wt % solutions 	 via CD, to ensure that conjugation to PEG did not signifi- 
of the PEG-HBP in PBS were added directly to 2.5 wt % 65 cantly alter the association of the PF 4ZIP coiled-coils. As 
solutions of the PEG-LMWH in PBS, to afford hydrogel 	 shown in FIG. 17(a), the spectra of PEG-PF 4ZIP are essen- 
networks at a final composition of 2.5 wt % total polymer. The 	 tially identical to the spectra obtained for the isolated PF4ZIP. 
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Slight differences in MRE values likely arise from uncertain-
ties in the precise peptide concentrations for the PEG-PF 4ZIP 
samples. The Kd value derived from the best fit of the con-
centration dependence of (FIG. 17(b)) for PEG-PF 4ZIP is 
0.93 µM. The PF4ZIP concentrations during NMR character-
ization and hydrogel formation and characterization are 
always much greater than these measured Kd values (e.g., 200 
µM and higher), suggesting that PF 4ZIP will exist as a fully 
folded dimer under those conditions. 
Heparin-Binding Affinity 
Our previous investigations of PEG-LMWH/PEG-HBP 
hydrogels suggested that the viscoelastic properties of the 
noncovalently assembled hydrogels were related to the hep-
arin-binding kinetics and affinities of the peptides (from anti-
thrombin III (ATIII) or heparin interacting protein (HIP)). 
Heparin-sepharose affinity chromatography and SPR experi-
ments were therefore used to compare the heparin-binding 
affinity of the various HBPs. Results of these experiments are 
summarized in Table 2. 
TABLE 2 
Heparin binding affinity data (at 25° C.) for heparin-binding peptides 
determined via affinity chromatography and SPR. The errors are 
derived from the average of duplicate measurements 
Salt required 
for elution 
from heparin 
Pep- 	 column 
tide 	 (MM) 	 ka (M
-IS  t ) 	 I" (S -1 ) 	 KD (PM) 
28 
Kiick, E. M. Furst, Rheological characterization ofpolysac-
charide poly(ethylene glycol) star copolymer hydrogels, 
Biomacromolecules 6 (4) (2005) 1931-1940) are the primary 
cause of the lower measured KD values for PF 4ZIP-LMWH 
5 binding, and the trend of the dissociation constants is consis-
tent with the chromatography results. The more rapid asso-
ciation rate, coupled with the similar dissociation rate, of 
PF4ZIP versus the other HBPs, points to the successful for-
mation of hydrogels between PEG-PF 4ZIP and PEG- 
10 LMWH. The measured KD of the binding between PF 4ZIP 
and LMWH is lower than the measured Kd of dissociation of 
the coiled-coil obtained from CD experiments, which may 
suggest that the LMWH-functionalized surface facilitates 
coiled-coil formation. Nevertheless, the equilibrium con- 
15 stants of dissociation determined via both methods are sub-
stantially lower than the concentrations employed during 
hydrogel formation experiments (see below). 
Temperature Dependence of PF 4ZIP Binding 
The heparin-binding kinetics between LMWH and PF 4ZIP 
20 were monitored via SPR at several temperatures between 5° 
C. and 37° C., to determine potential changes in binding 
kinetics that might alter hydrogel properties under physi-
ological conditions. Data from these experiments are shown 
in Table 3. 
25 
TABLE 3 
Heparin-binding affinity data for PF4, at different 
temperatures, as determined via SPR. The errors are derived 
30 	
from the average of duplicate measurements 
ATIII' 	 594 ± 2 1.56 ± 0.06 x 102 	 2.00 ± 0.3 x 10-3 	 12.9 ± 1.3 Temp- 
HIP' 	 687 ± 1 1.10 ± 0.08 x 103 	 4.64 ± 0.02 x 10-3 4.20 ± 0.3 erature 
PF4, 	 962 ± 10 2.24 ± 0.05 x 105 	 2.56 ± 0.10 x 10-3 1.15 ± (° C.) ka  (M-I s- 1
) I" (s t) KD (pM) 
0.03x10-2 5 1.56±0.01x105 3.74±0.17x10-3 2.41±0.10x10-8 
35 
'Data 15 1.90 ± 0.04 x 105 1.67 ± 0.03 x 10-3 8.82 ± 0.02 x 10
-g 
from previously reported 
M. Furst, Rheologieal characterization 
studies (N. Yamaguchi, B. S. Chae, L. Zhang, K. L. Kiicl,, E. 
ofpolysaeeharide-poly(ethylmeglyeol) star eopoly- 25 2.24 ± 0.05 x 105 2.56 ± 0.10 x 10-3 1.15 ± 0.03 x 10-8 
mer hydrogels, Biomacromolecules 6 (4) (2005) 1931-1940) 37 5.11 ± 0.02 x 105 2.44 ± 0.08 x 10-3 4.78 ± 0.14 x 10-g 
For heparin affinity chromatography experiments, HBPs 
were loaded onto a heparin-sepharose column, and then 
eluted with buffer of increasing NaCl concentration. The 
concentration of NaCl required for peptide elution is used as 
an indication of the affinity of the peptide for heparin. The 
elution of the peptides from the heparin-sepharose column 
required a salt concentration of 962±10 mM for the PF 4ZIP 
peptide. The salt concentration required to elute PF 4ZIP 
(962±10 mM) is higher than that measured for the ATIII 
peptide (594±2 mM) and for the HIP peptide (687±1 mM), 
indicating that PF 4ZIP has higher heparin-binding affinity 
than the ATIII and HIP peptides and should therefore be 
competent for hydrogel assembly. These results are consis-
tent with previous reports indicating that similarly high con-
centrations of NaCl were required to elute 125I-labelled 
PF4ZIP bound to a heparin-sepharose column in 0.02 M 
Tris-HCl buffer pH 7.0 containing 0.05 M NaCl. 
In SPR experiments, the interaction of the peptides with a 
LMWH-modified SA chip surface was determined under 
conditions described in the experimental section. Neither 
nonspecific binding of heparin-binding proteins to SA chips 
nor chip instability was observed in any of the SPR measure-
ments. In addition, no mass transport limitation or linked 
reactions were indicated. The measured association of the 
PF4ZIP with LMWH proceeds with a rate constant of 
2.24±0.05x105 M-1 s-' ,  whilethe dissociation proceeds with 
a rate constant of 2.56±0.10x10 -3 s -1 , yielding a KD of 
approximately 1.15±0.03x10-2 µM. These faster association 
kinetics, relative to those reported for the ATIII and HIP 
(Table 2) (see also N. Yamaguchi, B. S. Chae, L. Zhang, K. L. 
The measured on and off rates fluctuate only slightly 
40 throughout the temperature range, suggesting that nonco-
valently assembled hydrogels based on PF 4ZIP and LMWH 
interactions should exhibit consistent mechanical properties 
at these temperatures. 
PEG-LMWH/PEG-HBP Hydrogel Formation 
45 	 Via 1H  NMR spectroscopy, functionalization of the star 
PEG with HBPs was determined to be at least 59%, indicating 
that PEG-HBPs meet the functional requirement (at least one 
binding partner exhibits f>2) for crosslinking a hydrogel 
upon interaction with PEG-LMWH (which showed a func- 
50 tionalization of 81%, as determined via NMR). (see N. 
Yamaguchi, K. L. Kiick, Polysaccharide poly (ethylene gly-
col) star copolymers as scalblds for the production of bioac-
tive hydrogels, Biomacromolecules 6 (4) (2005) 1921-1930; 
and N. Yamaguchi, B. S. Chae, L. Zhang, K. L. Kiick, E. M. 
55 Furst, Rheological characterization of polysaccharide poly 
(ethylene glycol) star copolymer hydrogels, Biomacromol-
ecules 6 (4) (2005) 1931-1940). 
Accordingly, solutions of the two polymer conjugates in 
PBS (2.5 wt % of the PEG-LMWH and 5 wt % of the PEG- 
6o HBP) were mixed at various ligand molar ratios to form 
hydrogels. Ligand molar ratios of 9:0.5 and 7.5:2.5 (LMWH: 
PF4ZIP) were used to yield the PEG-LMWH/PEG-PF4ZIP 
hydrogels. Similar ratios were used for the formation of func- 
tionalized crosslinked matrices from mixtures of PEG- 
65 LMWH with either PEG-ATIII or PEG-HIP, and any PEG- 
HBP conjugate should be useful in a similar manner. The 
application of such ratios was employed to maximize the 
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excess LMWH available for growth factor binding (see 	 microrheology experiments, in this case, confirmed the elas- 
below). Before addition of PEG-PF 4ZIP, the 2.5 wt % of the 	 tic behavior of the hydrogels at low and moderate frequen- 
PEG-LMWH was uniform and translucent. In addition, the 	 cies, and also demonstrated that the development of elastic 
water-like viscosity of the PEG-PF 4ZIP solution indicated 	 properties of the network are dependent on the concentration 
that there was no significant crosslinking of the peptide- 5 of VEGF present in the network. Microrheology character- 
terminated star polymers via intermolecular coiled-coil for- 	 ization was conducted on 4 wt % hydrogels in order to reduce 
mation, although some oligomers of the PEG-PF 4ZIP bio- 	 the elastic modulus sufficiently for measurement. 8 wt % 
conjugates may exist in solution. The formation of self- 	 hydrogels provide improved mechanical properties, although 
supporting, opaque gels was immediately apparent upon 	 a variety of concentrations could be used depending on the 
mixing the two polymer solutions. A schematic of the assem-  io desired application. 
bly of the hydrogels is shown in FIG. 18. This assembly is 	 The theological properties of the PEG-LMWH/PEG- 
operative regardless of the identity of the PEG-HBP. 	 PF4ZIP hydrogels were also investigated at physiological 
Bulk Rheology 	 temperature. The mechanical properties of the hydrogels with 
The mechanical properties of the PEG-HBP containing 	 molar ratios of LMWH to PF 4ZIP of 9:0.5 and 7.5:2.5 were 
hydrogels were characterized via theological frequency 15 examined. The frequency sweep data for the hydrogel 
sweep experiments on bulk samples. The frequency sweep 	 (LMWH:PF4ZIP=9:0.5) are presented in FIG. 21. The 
results for PEG-LMWH/PEG-PF 4ZIP hydrogels (FIG. 19) 	 moduli at 25° C. or 37° C. are essentially identical, with an 
show that the storage modulus G'(w) is significantly larger 	 identical frequency dependence, although the gels at 37° C. 
than the loss modulus G"(w) over all measured frequencies 	 exhibit slightly lower loss moduli at higher frequencies. The 
and G'(w) exhibits a pronounced plateau extending to fre-  20 materials are therefore also elastic hydrogels at 37° C., in 
quencies of tens of reciprocal seconds, indicating a viscoelas- 	 corroboration of the SPR studies. This lack of temperature 
tic gel. Essentially identical results are obtained regardless of 
	
dependence is also observed in the hydrogel with higher 
the identity of the PEG-HBP. The magnitude of G'(w) and 	 PF4ZIP content, reflecting the temperature insensitivity of 
G"(w) also increases as the molar ratio of the peptide com- 	 both the PF4 LMWH interactions and the LMWH-LMWH 
ponent is raised. The average G'(w) increases from an average 25 interactions. 
value of 70 Pa for PEG-LMWH to approximately 80 and 180 
	
Shear recovery data for the PEG-LMWH/PEG-PF 4ZIP 
Pa for hydrogels with molar ratios of LMWH to PF4ZIP of 
	
hydrogels are exhibited in FIG. 22. Both the extent and time- 
9:0.5 and 7.5:2.5, respectively. The average G"(w) also 	 dependence of recovery were determined in these experi- 
increases monotonically with higher molar ratio of the pep- 	 ments. FIG. 22 indicates that after the hydrogels are subjected 
tide component, from less than 10 Pa for PEG-LMWH to 30 to a steady shear rate as high as 1000 s -i , they essentially 
more than 30 Pa for hydrogels with molar ratios of LMWH to 	 immediately recover their elastic properties, so only a slight 
PF4ZIP of 7.5:2.5. Bulk theology experiments were also 	 reduction in modulus can be measured. In addition, the 
performed on the samples at various gap heights of 1 mm, 0.5 	 moduli at 25° C. and 37° C. are equal, with a matching 
mm, and 0.25 mm. At frequencies from 0.1 to 63 Hz, the 	 kinetics of recovery. The data are consistent with previous 
observed identical dynamic moduli at different gap heights 35 theological frequency sweep studies (FIG. 21). The immedi- 
indicate that no significant slipping occurs in that frequency 	 ate recovery and stability of the PEG-LMWH/PEG-PF4ZIP 
range. 	 hydrogels even after subjected to high shear suggests their 
The strengthening effects on storage modulus upon addi- 	 potential utility in injectable applications. 
tion of PEG-HBP to PEG-LMWH are presented in FIG. 20 
	
Growth Factor Release and Hydrogel Erosion 
for G'(w-0. I Hz) plotted as a function of the ratio of HBP to 40 	 The release of growth factors from these hydrogels in vitro 
LMWH in the samples, with moduli normalized by the initial 
	
has also been investigated. Although covalently crosslinked, 
storage modulus of PEG-LMWH. The plateau in the modulus 	 heparin-containing hydrogels have been shown to be useful 
with increasing PF 4ZIP or HIP concentration may imply that 	 for release of bFGF, physically crosslinked hydrogels could 
the HBP-binding sites on LMWH have been saturated. The 	 provide an alternative protein-delivery matrix without the 
increase in the elastic modulus upon addition of PEG-PF 4ZIP 45 need for potentially toxic crosslinking reagents. 
for the PEG-LMWH/PEG-PF 4ZIP hydrogels is lower than 	 The bFGF release and hydrogel erosion experiments were 
that observed with addition of PEG-HBP for the PEG- 	 performed at 4° C. in 24-well polystyrene assay plates. A 2.5 
LMWH/PEG-ATIII or the PEG-LMWH/PEG-HIP hydro- 	 wt % solution of PEG-LMWH with bFGF was prepared via 
gels. Literature reports suggest that at least 4 tetrasaccharides 	 dissolving PEG-LMWH and bFGF in PBS at a final molar 
(16 units) are required for efficient heparin-PF4 protein inter-  5o ratio of approximately 1:1,500,000 (bFGF to LMWH). Sec- 
actions, while HIP- andATIII-binding sites are believed to be 	 ondly, a 5 wt % solution of PEG-PF 4ZIP (or other PEG-HBP) 
similar pentasaccharides in heparin. The fewer PF 4-binding 	 in PBS was added to the PEG-LMWH/bFGF at a ligand molar 
sites on LMWH could lead to the lower storage modulus 	 ratio of 8:1 (LMWH:PF4ZIP dimer). Other molar ratios can 
plateau value and lower slope in FIG. 20 for the PEG- 	 also be used, depending upon the desired rate of release of the 
LMWH/PEG-PF4ZIP hydrogels than that observed for the 55 growth factor and/or desired rate of erosion of the network. 
PEG-LMWH/PEG-ATIII or the PEG-LMWH/PEG-HIP 
	
Assuming that all HBPs on the PEG-HBP termini bind 
hydrogels. These results indicate two things. First, the 	 LMWH, the molar ratio of bFGF to available LMWH in the 
mechanical properties of the hydrogels are initially estab- 	 PEG-LMWH/PEG-HBP hydrogels is approximately 
lishedby the self-interaction/assembly of PEG-LMWH. Sec- 	 1:1,300,000. 
ond, the dependence of storage modulus on HBP:LMWH 60 Data from studies of bFGF release from PEG-LMWH/ 
ratio clearly indicates that the PEG-HBPs mediate crosslink- 	 PEG-HIP and PEG-LMWH/PEG-PF 4ZIP hydrogels are 
ing of the networks and that the interactions between HBP 	 summarized in FIG. 23. As shown in the figure, a burst release 
and LMWH modulate the mechanical properties of the matri- 	 of bFGF ranging from 10 to 25% (depending on gel identity) 
ces. 	 is observed, followed by a slow release of bFGF over 10 days, 
A similar dependence of theological properties on the con-  65 to a maximum measured release ranging from approximately 
centration of heparin-binding cross-linker was observed for 	 20 to 35%. Such release profiles are of potential use in 
PEG-LMWH crosslinked with VEGF. Laser tweezer 	 neovascularization, wound repair, and tissue engineering 
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applications. As shown in FIG. 23, the bFGF is released 
slightly more quickly from the PEG-LMWH/PEG-PF 4ZIP 
hydrogels than from the PEG-LMWH/PEG-HIP hydrogels, 
indicating that the rates of release of growth factor from these 
hydrogels are tunable based on hydrogel composition. The 
PEG-LMWH/PEG-HIP hydrogel demonstrates higher stor-
age and loss moduli than the PEG-LMWH/PEG-PF 4ZIP 
hydrogels. The observed burst release is similar in value to 
previously reported burst release in other heparinized hydro-
gel system, and the linear release following the initial burst in 
those hydrogel systems has been successfully applied to 
stimulate cell proliferation. 
Hydrogel erosion kinetics are also shown in FIG. 23. In the 
case of the PEG-LMWH/PEG-PF 4ZIP hydrogels, PEG-
LMWH-Alexa Fluor 350 was pre-mixed with PEG-LMWH 
at a weight ratio of 1:158 to facilitate tracking of the eroded 
PEG-LMWH via fluorimetry. The erosion profile of the PEG-
LMWH/PEG-HIP hydrogels was determined gravimetrically 
in the transwell assay format in conjunction with the bFGF 
release experiments. As shown in the figure, a burst erosion of 
10 to 30% is initially observed (depending on hydrogel com-
position), followed by a slow erosion to a maximum of 30 to 
50% (again, depending on hydrogel composition). As is also 
indicated in this figure, the growth factor release is directly 
correlated to the erosion of the hydrogel, and can therefore be 
controlled by modulating hydrogel mechanical properties. 
Modulating the affinity of the growth factor to the hydrogel 
will also serve as an additional strategy to control release 
rates. 
Growth factors released from hydrogels of these general 
compositions have also been shown to be bioactive, indicat-
ing the utility of these matrices in desired applications. For 
example, bFGF released from PEG-LMWH functionalized 
hydrogels (covalently crosslinked model systems) (proce-
dure for covalent crosslinking is provided in N. Yamaguchi, 
K. L. Kiick, Polysaccharide poly (ethylene glycol) star 
copolymers as scalblds for the production ofbioactive hydro-
gels, Biomacromolecules 6 (4) (2005) 1921-1930, which is 
incorporated herein by reference) has been shown, via MTT 
(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) proliferation assays, to increase proliferation of 
HUVECs (human umbilical vein endothelial cells) in a 
bFGF-dose-responsive manner. In these assays, the amount 
of yellow MTT oxidized to purple formazan is measured 
spectrophotometrically as a function of the amount of bFGF 
loaded in the hydrogel. Average increases in formazan salt 
formation ranged from 1.5 to 4 fold in the bFGF proliferation 
experiments. In another set of experiments, VEGF released 
from the PEG-LMWH/VEGF hydrogels has been shown to 
increase the rate of proliferation of porcine aortic endothelial 
(PAE) cells in DMEM media. Assays were conducted in a 
transwell assay format as described in N. Yamaguchi, K. L. 
Kiick, Polysaccharide poly (ethylene glycol) star copolymers 
as scafblds for the production of bioactive hydrogels, Biom-
acromolecules 6 (4) (2005) 1921-1930. Measured increases 
in the proliferation rate, assessed via cytometry, have ranged 
from 25-50%. These results complement and are similar to 
the results obtained in Example 3, which indicate the bioac-
tivity of growth factor-loaded electrospun matrices. Similar 
bioactivity of any growth factor sequestered in these matrices 
is expected, based on these results, and on the general obser-
vation of growth factor activity preservation in heparinized 
matrices. 
Example 5 
Electrospinning Fibers of Polyurethane or Collagen 
Methods for preparing electrospun polyurethane fibers are 
known in the art, e.g., Rockwood, et al., J. Biomaterials 
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Science, Polymer Edn. 18: 743-758, 2007. Briefly, an 18% 
wt/vol solution of polyurethane (PU) was prepared in dichlo-
romethane. Microfibers were spun on an electrospinning 
apparatus consisting of a syringe pump (Orion Sage m,  
5 Fisher, Fair Lawn, N.7.), high voltage supply (Glassman 
Series EH, High Bridge, N.7.), 5 ml glass syringe with a 23 
gauge stainless steel needle attached at a working distance of 
25 cm. A voltage of 10 kV was applied between the needle 
and the grounded collector plate. Large mats of electrospun 
10 fibers were collected on a grounded mandrel that slowly 
oscillated in the tansverse direction at 5 m/sec and rotated at 
0.133 m/sec. Smaller mats were collected on a stationary 
target. 
Electrospun collagen fibers were prepared as previously 
15 described, Hartman, et al., Biomacomolecules 10: 2019-
2032, 2009. Briefly, collagen fibers were electrospun from a 
12% wt/vol solution of collagen type I in hexafluoroisopro-
panol using the same processing parameters as described in 
Example 1. LMWH-PEG was incorporated into the fiber as 
20 described in Example 1 and in Casper, et al., Biomacromol-
ecules 6: 1998-2007, 2005. 
Example 6 
25 	 Release of Growth Factors from Electrospun Fibers 
Platelet derived growth factor (PDGF) and basic fibroblast 
growth factor (bFGF) were obtained commercially from 
R&D Systems, Minneapolis, Minn. Vascular epidermal 
30 growth factor (VEGF 165) was expressed from E.coli with the 
glycine residues of the growth factor replaced by 3H-glycine. 
3H-VEGF 165 was produced by E. coli grown on minimal 
medium that was supplemented with 3H-glycine just prior to 
induction of protein expression. 
35 All samples were 6 mm disks of approximately 1 mg mass. 
All heparin species were at 100 µM concentration. Growth 
factor release studies were carried out using scintillation 
counting (VEGF) or enzyme immunoassay (PDGF and 
bFGF). Growth factor binding to the electrospun PLGA, PU 
4o and collagen matrices was performed in 24-well polystyrene 
plates (Corning Inc., Corning, N.Y.) with 8 M pore size 
transwell membranes (Fisher Scientific, Atlanta, Ga.) to keep 
the electrospun matrices submerged during the release study. 
The 24 well plate and transwell membranes were blocked 
45 with a 3% BSA (Sigma Aldrich, St. Louis, Mo.) in PBS 
(Invitrogen, Carlsbad, Calif.) solution for 24 hours. All 
samples were washed three times with PBS and then incu-
bated with 100 ng growth factor in 1 ml PBS for 2 hours at 
room temperature with the transwell membrane in place. 
5o After 2 hours of incubation the PBS was removed and 
replaced with 1 ml of PBS containing no growth factor. All 
samples were incubated at 37° C. in a humid atmosphere with 
5% CO2 in a NAPCO 6000 incubator. Each 1 ml aliquot of 
PBS was removed from the 24 well plate on a 24 hour basis to 
55 determine the amount of growth factor released in that time 
period. Each well was refilled with 1 ml of fresh PBS after 
each aliquot was removed for scintillation counting. Serum-
free DMEM may be used as an alternative to PBS in these 
experiments. 
60 	 To measure 3 H-VEGF 165, aliquots were placed in 10 ml 
scintillation vials with 5 ml of Fisher ScintiSafe Econo 2 
scintillation fluid (Fisher Scientific, Atlanta, Ga.), vortexed 
for 30 seconds and counted for 1 minute in a Beckman 
Coulter LS6500 (Beckman Coulter, Brea, Calif.) scintillation 
65 counter to determine the rate of growth factor release during 
each time interval. Commercially available assay kits from 
R&D Systems were used to measure released PDGF and 
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bFGF. Release values are based on the total amount of growth 
factor in each fibrous mat prior to the release studies. 
Heparinized mats sequestered about 100% of the growth 
factor initially applied, while non-heparinized mats seques-
tered about 50-57% of the applied growth factor. Release 
profiles for VEGF, PDGF, and bFGF are shown in FIG. 24. 
Approximate release values over 7 days were 20% for PDGF 
and VEGF and 40% for bFGF, corresponding, in these 
examples, to approximately 20 ng of PDGF or VEGF and 40 
ng of bFGF. Electrospun fibers modified with high molecular 
weight heparin (HMWH) showed almost complete release 
34 
(100%) of growth factor within 2 days. In contrast, matrices 
modified with PEG-LMWH showed a linear release of 
growth factor over a period greater than 7 days. Electrospun 
fibers modified with free LMWH (not conjugated to PEG) 
5 exhibited release profiles similar to those seen in non-hep-
arinized mats. These results demonstrate that the conjugation 
of LMWH to a short polymeric chain permits facile function-
alization of fibers, retention of PEG-LMWH to provide func-
tional activity of LMWH in the matrices, and thus allows for 
to retention and significantly slowed release of growth factors 
from the matrix over time. 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 9 
<210> SEQ ID NO 1 
<211> LENGTH: 34 
<212> TYPE: PRT 
<213> ORGANISM: Artificial sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<400> SEQUENCE: 1 
Cys Gly Gly Arg Met Lys Gin Leu Glu Asp Lys Val Lys Lys Leu Leu 
1 	 5 	 10 	 15 
Lys Lys Asn Tyr His Leu Glu Asn Glu Val Ala Arg Leu Lys Lys Leu 
20 	 25 	 30 
Val Gly 
<210> SEQ ID NO 2 
<211> LENGTH: 15 
<212> TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<220> FEATURE: 
<221> NAME/KEY: MISC_FEATURE 
<222> LOCATION: (3)..(3) 
<223> OTHER INFORMATION: Ala is beta-alanine 
<400> SEQUENCE: 2 
Cys Lys Ala Phe Ala Lys Leu Ala Ala Arg Leu Tyr Arg Lys Ala 
1 	 5 	 10 	 15 
<210> SEQ ID NO 3 
<211> LENGTH: 16 
<212> TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<400> SEQUENCE: 3 
Cys Arg Pro Lys Ala Lys Ala Lys Ala Lys Ala Lys Asp Gin Thr Lys 
1 	 5 	 10 	 15 
<210> SEQ ID NO 4 
<211> LENGTH: 12 
<212> TYPE: PRT 
<213> ORGANISM: Artificial sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<400> SEQUENCE: 4 
Trp His Ser Asp Met Glu Trp Trp Tyr Leu Leu Gly 
1 	 5 	 10 
<210> SEQ ID NO 5 
<211> LENGTH: 7 
<212> TYPE: PRT 
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-continued 
<213> ORGANISM: Artificial sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<400> SEQUENCE: 5 
Ala Thr Trp Leu Pro Pro Arg 
1 	 5 
<210> SEQ ID NO 6 
<211> LENGTH: 12 
<212> TYPE: PRT 
<213> ORGANISM: Artificial sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<400> SEQUENCE: 6 
His Thr Met Tyr Tyr His His Tyr Gin His His Leu 
1 	 5 	 10 
<210> SEQ ID NO 7 
<211> LENGTH: 15 
<212> TYPE: PRT 
<213> ORGANISM: Artificial sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<400> SEQUENCE: 7 
Lys Leu Thr Trp Gin Glu Leu Tyr Gin Leu Lys Tyr Lys Gly Ile 
1 	 5 	 10 	 15 
<210> SEQ ID NO 8 
<211> LENGTH: 16 
<212> TYPE: PRT 
<213> ORGANISM: Artificial sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<400> SEQUENCE: 8 
Cys Lys Ala Ala Lys Arg Pro Lys Ala Ala Lys Asp Lys Gin Thr Lys 
1 	 5 	 10 	 15 
<210> SEQ ID NO 9 
<211> LENGTH: 12 
<212> TYPE: PRT 
<213> ORGANISM: Artificial sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<400> SEQUENCE: 9 
Cys Gly Gly Arg Arg Arg Arg Arg Arg Arg Gly Gly 
1 	 5 	 10 
What is claimed: 
1. A functionalized polymer matrix for the controlled 
55 
release in vitro or in vivo of a growth factor, the functionalized 
polymer matrix comprising a matrix polymer, a compatibi-
lizing polymer comprising PEG, a low molecular weight 
heparin and at least one releasable growth factor, wherein the 
low molecular weight heparin is covalently attached to the 60 
compatibilizing polymer, and wherein the compatibilizing 
polymer comprises between about 0.35% wt/wt and about 
0.95% wt/wt of the polymer matrix, wherein controlled 
release of the growth factor from the functionalized polymer 65 
matrix exhibits a linear controlled-release profile over at least 
seven days. 
2. The functionalized polymer matrix of claim 1, wherein 
the matrix polymer comprises polyurethane, collagen, PEO, 
PLGA, or combinations thereof. 
3. The functionalized polymer matrix of claim 1, wherein 
the at least one releasable growth factor is selected from the 
group consisting of PDGF, VEGF, and bFGF. 
4. The functionalized polymer matrix of claim 3, wherein 
the at least one releasable growth factor is PDGF. 
5. The functionalized polymer matrix of claim 3, wherein 
the at least one releasable growth factor is VEGF. 
6. The functionalized polymer matrix of claim 3, wherein 
the at least one releasable growth factor is bFGF. 
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7. The functionalized polymer matrix of claim 2, wherein 
the matrix polymer comprises polyurethane. 
8. The functionalized polymer matrix of claim 2, wherein 
the matrix polymer comprises collagen. 
9. The functionalized polymer matrix of claim 2, wherein 
the matrix polymer comprises PEO. 
10. The functionalized polymer matrix of claim 2, wherein 
the matrix polymer comprises PLGA.  
38 
11. The functionalized polymer matrix of claim 1, wherein 
50% or less of the growth factor is released from the polymer 
matrix over seven days. 
12. The functionalized polymer matrix of claim 1, wherein 
the at least one growth factor is non-covalently bound to the 
low molecular weight heparin. 
